WO2007127150A1 - Compensation reduction in tissue stimulation therapy - Google Patents
Compensation reduction in tissue stimulation therapy Download PDFInfo
- Publication number
- WO2007127150A1 WO2007127150A1 PCT/US2007/009723 US2007009723W WO2007127150A1 WO 2007127150 A1 WO2007127150 A1 WO 2007127150A1 US 2007009723 W US2007009723 W US 2007009723W WO 2007127150 A1 WO2007127150 A1 WO 2007127150A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- time
- duty cycle
- event
- setting
- electrical signal
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 71
- 230000000638 stimulation Effects 0.000 title description 8
- 230000009467 reduction Effects 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 25
- 230000004913 activation Effects 0.000 claims abstract description 12
- 230000008859 change Effects 0.000 claims abstract description 4
- 210000005036 nerve Anatomy 0.000 claims description 21
- 210000001186 vagus nerve Anatomy 0.000 claims description 16
- 230000004044 response Effects 0.000 claims description 12
- 230000035790 physiological processes and functions Effects 0.000 claims description 5
- 238000001994 activation Methods 0.000 abstract description 10
- 210000001519 tissue Anatomy 0.000 description 19
- 238000010926 purge Methods 0.000 description 10
- 230000008901 benefit Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 206010006550 Bulimia nervosa Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 208000032841 Bulimia Diseases 0.000 description 2
- 235000014676 Phragmites communis Nutrition 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000030814 Eating disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 210000001932 glossopharyngeal nerve Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
- A61N1/3606—Implantable neurostimulators for stimulating central or peripheral nerve system adapted for a particular treatment
- A61N1/36082—Cognitive or psychiatric applications, e.g. dementia or Alzheimer's disease
Definitions
- the subject matter of this disclosure generally relates to the field of implantable medical devices. More specifically, the present disclosure relates to reducing compensation in tissue stimulation therapy, and particularly electrical neurostimulation therapy.
- Implantable medical devices are used to treat a variety of diseases and disorders.
- Some types of IMDs apply an electrical signal to a patient's body tissue to which the IMD is coupled.
- a neurostimulator can be coupled to a patient's vagus nerve to provide an electrical signal to the nerve to treat seizure disorders such as epilepsy.
- Providing an electrical signal to the vagus nerve can also be therapeutically beneficial to treat other conditions, including depression and various eating disorders such as bulimia nervosa.
- the body is known to compensate or alter its response to repeated stimuli. For example, after receiving an electrical neurostimulation therapy over an extended period of time, the body may adapt or compensate in response to the repeated application of the electrical signal, thereby rendering the therapy provided by the IMD less beneficial.
- a healthcare provider may adjust the operation of the IMD.
- An IMD adjustment may involve altering one or more operating parameters that define the electrical signal, such as current amplitude, pulse width, pulse frequency, on time, off time, etc.
- the body eventually may again compensate to the therapy provided by the IMD, thereby again rendering the therapy provided by the IMD less beneficial. Numerous adjustments may thus be required because the body may continually compensate to the therapy.
- Each IMD adjustment usually requires a visit to the physician that, for many patients, is time- consuming, expensive, and generally undesirable.
- the present disclosure addresses the issues noted above by reducing or preventing the body from compensating to a given therapy protocol delivered by an implanted medical device.
- the disclosed techniques involve a change from a first therapy protocol to a second therapy protocol based on the occurrence of an event (e.g., an elapsed time interval, user activations of the therapy, input from a physiological sensor, etc.).
- the first and second therapy protocols differ in terms of the on-time and off- time, but effectuate the same or a similar duty cycle. Therapy protocols that have the same duty cycle, albeit with different settings for on-time and off-time, may result in similar therapeutic benefits to the patient.
- the implanted medical device preferably switches from the first such therapy protocol to the second before the body has a chance to compensate for the first therapy protocol.
- a method comprises delivering an electrical signal to a nerve according to a first setting of an on-time and off-time that defines a duty cycle.
- the method also comprises automatically changing the first setting to a second setting of on-time and off-time in response to an event.
- the second setting defines a duty cycle substantially equal to the duty cycle defined by the first setting.
- a system comprises a pulse generator that provides an electrical signal to a nerve and a controller coupled to the pulse generator.
- the controller causes the pulse generator to deliver an electrical signal to a nerve according to a first setting of an on-time and off-time that defines a duty cycle.
- the controller also causes a change from the first setting to a second setting of an on-time and off-time that defines the same or similar duty cycle as defined by the first setting.
- FIGURE 1 depicts, in schematic form, an implantable medical device, in accordance with a preferred embodiment of the invention, implanted within a patient and programmable by an external programming system;
- FIGURE 2 is a block diagram of the implantable medical device of Figure 1 and comprising a user input sense device
- FIGURE 3 illustrates a flow diagram of an embodiment of a method for treating or preventing compensation in tissue stimulation therapy.
- VNS vagus nerve stimulation
- the disclosure and claims that follow are not limited to VNS, and may be applied to the delivery of an electrical signal to modulate the electrical activity of other cranial nerves such as the trigeminal and/or glossopharyngeal nerves, or to other neural tissue such as one or more brain structures of the patient, spinal nerves, and other spinal structures.
- other embodiments of the invention can be implemented to stimulate tissue other than nerves or neural tissue, such as cardiac tissue, muscle tissue, connective tissue, or bone tissue.
- various embodiments of the invention comprise an implantable medical device (IMD) that alters its therapy protocol to reduce or prevent the body from compensating to the therapy.
- IMD implantable medical device
- the therapy protocol provided by the IMD comprises an electrical signal applied to a target tissue, with the signal characterized by a set of parameters.
- the parameters comprise, in at least some embodiments, pulse frequency, pulse width, current amplitude, on-time, and off-time.
- One therapy protocol differs from another therapy based on differences in the underlying parameters that define each therapy protocol.
- the "on-time” refers to the time period during which the IMD is actively stimulating tissue and the “off- time” refers to the time period in which no stimulation is provided.
- the IMD described herein provides a therapy protocol in which a therapy signal (which may comprise an electrical signal, a mechanical signal such as a vibration signal, an optical signal, a chemical signal, or another type of signal) is provided to the target tissue for an on-time and then turned off (i.e., not provided to the target tissue) during an off-time.
- a therapy signal which may comprise an electrical signal, a mechanical signal such as a vibration signal, an optical signal, a chemical signal, or another type of signal
- the therapy protocol then typically repeats itself over and over until the IMD is reprogrammed, or another intervention occurs, such as a manual intervention by the patient to temporarily deliver a different protocol for a short time period.
- the electrical signal is typically applied to the nerve as a pulsed electrical signal that is defined by a plurality of parameters. These may include current amplitude, pulse width, and pulse frequency.
- the electrical signal as thus defined is typically applied to the nerve in a series of pulses known as a burst.
- the burst is defined by an on-time, e.g., 30 seconds.
- the on-time includes interpulse periods in which no electrical pulse is being applied to the nerve.
- the on-time period is followed by an off- time period in which no signal is applied to the nerve.
- the therapy is provided by cycling between on-time and off-time periods.
- the "duty" cycle" of such a therapy protocol is the percentage of time in which the signal is being provided to the target tissue, i.e., it is the ratio of on-time to the sum of on-time and off-time. For example, a 50% duty cycle means that the on-time is equal to the off-time, and the electrical signal is being provided half of the time. It is important to note that where the signal is a pulsed signal, an electrical pulse is actually applied to the nerve for a small fraction of the total on-time.
- duty cycle is not the percentage of time that electrical charge is being delivered to the nerve, but the percentage of on-time to total time.
- the duty cycle may equal the percentage of time that charge is delivered to the nerve.
- any given duty cycle can be implemented with a variety of different on-time/off-time patterns.
- a 50% duty cycle can be implemented by a therapy protocol having an on-time of 10 seconds and an off-time of 10 seconds, as well as by a therapy protocol having an on-time of 15 seconds and an-off time of 15 seconds.
- Other therapy protocols having an equivalent duty cycle are obviously also available.
- the IMO automatically changes the on-time and off-time parameter settings periodically, without appreciably changing the duty cycle. It has been discovered that two or more therapy protocols having different on-time and off-time settings, while all other parameters remain substantially the same, including in particular duty cycle, may provide the same or similar therapeutic benefit to the patent while avoiding compensation for the signal that may reduce therapeutic benefit to the patient. Thus, in accordance with at least some embodiments, the IMD automatically changes the settings of on-time and off-time, while maintaining the duty cycle largely the same. Doing so reduces or avoids the body's tendency to compensate to the therapy protocol being delivered.
- FIG. 1 illustrates an implantable medical device (“IMD”) 110 implanted in a patient.
- IMD implantable medical device
- the IMD 110 may be representative of any of a variety of medical devices that provide a signal (e.g., an electrical, mechanical, chemical, or optical signal) to a target tissue of a patient.
- a signal e.g., an electrical, mechanical, chemical, or optical signal
- At least one preferred embodiment of the IMD 110 comprises a neurostimulator for applying an electrical signal to a neural structure in a patient, particularly a cranial nerve such as a vagus nerve 113.
- a lead assembly 116 is coupled to the IMD 110 and includes one or more electrodes, such as electrodes 112 and 114.
- Lead 116 has a proximal end that connects to the IMD 110 and a distal end on which the electrodes are provided.
- the outer housing (or "can") 129 of the IMD 110 preferably is electrically conductive and thus may also function as an electrode.
- the electrodes can be used to apply an exogenous electrical signal to and/or sense the electrical activity of the associated tissue (e.g., the vagus nerve 113).
- a strain relief tether 115 comprises an attachment mechanism to help secure the lead assembly 116 to the nerve 113 and to provide strain relief.
- An example of a suitable strain relief tether is described in U.S. Pat. No. 4,979,511, incorporated herein by reference.
- Figure 1 also illustrates an external programming system 120 comprising a programming device 124 coupled to a wand 128.
- the programming device 124 may comprise a personal computer, handheld computer (e.g., a personal digital assistant (PDA) device), or other suitable computing device consistent with the description contained herein.
- PDA personal digital assistant
- Methods and apparatus for communication between the IMD 110 and an external programming system 120 are known in the art.
- the IMD 110 includes a transceiver (such as a coil) that permits signals to be communicated wirelessly and non-invasively between the external wand 128 and the implanted IMD 110.
- the programming system 120 generally monitors the performance of the IMD 110 and downloads new programming parameters (e.g., on- time, off-time, pulse width, current amplitude, and pulse frequency) into the device to alter its operation as desired.
- new programming parameters e.g., on- time, off-time, pulse width, current amplitude, and pulse frequency
- FIG. 2 shows a block diagram of one embodiment of the IMD 110.
- the IMD 110 comprises a system that includes a battery 230, a pulse generator 232, and a controller 234. Under the control of controller 234, the pulse generator 232 generates an electrical signal to apply to a target tissue (e.g., a vagus nerve 113) in a patient.
- the battery 230 provides power to both the pulse generator 32 and, via the pulse generator, to the controller 234.
- the controller 234 generally assists, controls, and/or programs the pulse generator 232.
- Controller 234 preferably comprises a central processing unit (CPU) 236 such as a low-power, mixed-signal microcontroller. In general, any suitable processor can be used to implement some or all of the functionality explained herein.
- CPU central processing unit
- any suitable processor can be used to implement some or all of the functionality explained herein.
- the CPU 236 preferably couples to one or more analog-to-digital converters (ADCs) 48 and storage 240.
- the storage 240 preferably comprises volatile and/or nonvolatile memory.
- the non-volatile memory may comprise Flash memory.
- the volatile memory may comprise any suitable type of random access memory (RAM).
- the storage 240 is used to store code that is executed by the CPU 236.
- Such executable code may be loaded into the IMD 110 during manufacturing and/or may be downloaded to the IMD from the programming system 120 after implantation.
- the executable code may be loaded into non-volatile memory and either executed directly from the non-volatile memory or copied to the volatile memory for execution therefrom.
- the storage 240 or other storage (e.g., registers) in the pulse generator 232 may be used to store the parameter settings that define a therapy protocol or program.
- the IMD 110 may be programmed with a plurality of therapy protocols.
- the therapy protocols may be loaded into IMD 110 during manufacturing and/or downloaded to the IMD 110 from programming system 120 after implantation.
- the controller 234 can cause the pulse generator 232 to operate in accordance with any suitable therapy protocol from among one or more such protocols programmed into the IMD 110.
- the IMD 110 includes a user input sensor 260 and a physiological sensor 262.
- Sensor 260 is used to sense an external user input such as a tap, a magnetic field, a sound, etc.
- Sensor 260 can be used to provide manual control of the IMD 110 by a person (e.g., the patient in which the IMD is implanted).
- the sensor 260 is preferably integrated within the IMD 110, but in alternative embodiments can be physically separate.
- user input sensor 260 comprises an implanted tap sensor such as an accelerometer.
- the tap sensor provides an electronic signal to the IMD 110 in response to a patients' physical tap or touching of the skin over the location of the implanted tap sensor.
- the sensor 260 comprises a Reed switch that can be opened or closed by a magnet that is placed in close proximity to the IMD 110.
- the patient may be provided with a magnet that when placed near the IMD provides a magnetic field as an input to the Reed switch, to thereby control one or more operations of the IMD 110.
- Sensor 262 is sensitive to a physiological parameter of the patient in which the IMD 110 is implanted. Any number of such sensors may be included for sensing one or more physiological parameters of the patient's body functions.
- Physiological sensor(s) 262 may comprise any or all of the following non-limiting examples: electrodes that sense electrical activity, a pressure transducer, an acoustic element, a photonic element, a blood pH sensor, a blood pressure sensor, a blood sugar sensor, and a body movement sensor.
- the sensors 262 that are coupled to the IMD 110 are capable of sensing one or more physiological parameters selected from the following exemplary list: an action potential in a nerve tissue, a heart parameter, a body temperature, a blood parameter (e.g., pH, pressure), food intake, gastric (e.g., stomach and/or intestinal) function, and brain activity.
- physiological parameters selected from the following exemplary list: an action potential in a nerve tissue, a heart parameter, a body temperature, a blood parameter (e.g., pH, pressure), food intake, gastric (e.g., stomach and/or intestinal) function, and brain activity.
- FIG. 3 illustrates a method 300 for reducing compensation of the patient's body to a therapy protocol performed by an IMD.
- an electrical signal is delivered to a target tissue (e.g., a vagus nerve) by the IMD 110 according to a first therapy protocol having a first setting of on-time and off-time which defines a particular duty cycle.
- the IMD 110 determines the occurrence of an event.
- the event in block 304 comprises the expiration of a time period associated with the first on-time/off-time setting. That time period can be any fixed or programmable period of time such as 1 hour, 1 day, 1 month, etc.
- the event may comprise a user activation parameter that is manually provided by a user to the user input sensor 260, or a physiological event that may be automatically sensed by physiological sensor 262 ( Figure 2).
- the IMD 110 at block 306 changes the first on-time/off-time setting to a second on-time/off- time setting while maintaining the same or a substantially similar duty cycle, and delivers to the target tissue an electrical signal according to a second therapy protocol employing the second on-time/off-time setting.
- the therapy protocol changes in block 306 relative to the therapy protocol of block 302 but, with the duty cycle remaining the same, the therapeutic efficacy of the therapy protocol may be maintained or improved.
- the IMD in block 308 again determines whether an event has occurred.
- the event in block 308 may comprise an event of the type referred to in regard to block 304, e.g., a time period associated with the second on-time/off-time setting or a physiological event sensed by physiological sensor 262.
- the IMD 110 continues providing an electrical signal according to the second therapy protocol and the second on- time/off-time setting for a fixed or programmable period of time that may the same as, or different from, a time period associated with the first on-time/off-time setting and the first therapy protocol.
- control reverts back to block 302 at which the process repeats.
- Each setting for on-time and off- time may be computed based on a prior setting.
- the IMD 110 thus provides an electrical signal to target tissue in alternating fashion in accordance with the first therapy protocol defined by a first on-time/off-time setting and then in accordance with the second therapy protocol defined by a second on-time/off-time setting.
- more than two therapy protocols with the same or similar duty cycle can be implemented.
- three therapy protocols can be implemented sequentially, each therapy being implemented for a specific period of time.
- the events occurring in blocks 304 and 308 may be other than time periods.
- the event may be indicated manually by a user via user input sensor 260.
- a user input such as a magnet may be used to signal any of a variety of user activation parameters, such as an indication of a binge/purge episode, a desire for therapy, or other parameters indicating an input from a user (e.g., the patient or a physician).
- a physiological sensor 262 can be used to automatically detect one or more body parameters, changes of which in excess of a threshold value are the event.
- the event may be physiological in nature such as, via a sensor 260 or 262, a bulimia patient binging and/or purging, either a single episode of binging and/or purging or binging and/or purging in excess of a predefined or programmable rate.
- Episodes of binging and/or purging can be detected by a variety of methods, including a manual indication by the patient or automatic detection of a body parameter such as swallowing, automatically detected gastric motility motion (e.g., stomach contractions), blood parameters such as a rapid increase in blood sugar or insulin secretion (which may be indicated either automatically via physiological sensor 262 or manually via user input sensor 260 after a conventional blood glucose test), sensed vagus nerve electrical activity, and other physiologically sensed body parameters.
- the events in blocks 304, 308 comprise the determination that the patient has communicated (e.g., via tapping, a magnet, etc.) with a user input sensor 260 more than a threshold number of times in a given period of time.
- a bulimia patient can manually activate the sensor 260 each time the patient feels a desire to binge or purge. If the rate at which the patient feels a need to binge and/or purge exceeds a specified rate, the IMD 110 will automatically switch to the next scheduled therapy protocol.
- switching from one therapy protocol to the next can be based on time, based on a rate at which the user activates sensor 260, or based on a detection of physiological events (e.g., binging/purging). Further still, switching from one therapy protocol to the next can occur based on one or more of the expiration of defined time periods for each therapy protocol, manual activation of user input sensor 260, and/or detection of a physiological event. For example, the IMD 110 switches from one therapy protocol to another at defined time intervals, but one therapy protocol can be terminated prematurely in favor of the next scheduled therapy protocol if the user activates the sensor device 260 at a rate greater than a threshold rate.
- user input sensor 260 can also be used by a person (e.g., the patient in which the IMD 110 is implanted) to provide additional information to the IMD 110.
- the IMD's controller 234 determines an action to be performed according to the number of user activations of the user input sensor 260. For example, a patient may activate the user input sensor device 260 once to signify the occurrence of a physiological or psychological event (e.g., the desire to binge or purge). The IMD 110 may then record in, for example, storage 240 that such an event has occurred.
- Such information can be used for a variety of purposes such as verifying the accuracy of what a bulimic patient reports to a healthcare provider regarding his or her desire to binge and purge.
- user activations of the user input sensor 260 can be performed to cause the IMD 110 to deliver an immediate stimulation.
- the number of user activations may encode the type of stimulation to be delivered.
- three activations of sensor 260 in quick succession may cause the IMD 110 to deliver a larger stimulation level (e.g., greater current amplitude) than two activations of sensor 260 in quick succession.
Abstract
Methods and systems for reducing compensation of the body to therapy delivered by an implanted medical device are described herein. The disclosed techniques cause a change from one therapy protocol to another therapy protocol based on the occurrence of an event (e.g., time, user activations of a sensor, input from a physiological sensor, etc.). The therapy protocols of the implanted medical device differ in terms of the on-time and off-time, but effectuate the same or similar duty cycle.
Description
COMPENSATION REDUCTION IN TISSUE STIMULATION THERAPY
BACKGROUND Technical Field
[0001] The subject matter of this disclosure generally relates to the field of implantable medical devices. More specifically, the present disclosure relates to reducing compensation in tissue stimulation therapy, and particularly electrical neurostimulation therapy.
Background Information
[0002] Implantable medical devices (IMDs) are used to treat a variety of diseases and disorders. Some types of IMDs apply an electrical signal to a patient's body tissue to which the IMD is coupled. For example, a neurostimulator can be coupled to a patient's vagus nerve to provide an electrical signal to the nerve to treat seizure disorders such as epilepsy. Providing an electrical signal to the vagus nerve can also be therapeutically beneficial to treat other conditions, including depression and various eating disorders such as bulimia nervosa.
[0003] The body is known to compensate or alter its response to repeated stimuli. For example, after receiving an electrical neurostimulation therapy over an extended period of time, the body may adapt or compensate in response to the repeated application of the electrical signal, thereby rendering the therapy provided by the IMD less beneficial. When this happens, a healthcare provider may adjust the operation of the IMD. An IMD adjustment may involve altering one or more operating parameters that define the electrical signal, such as current amplitude, pulse width, pulse frequency, on time, off time, etc. After the adjustment has been made to the electrical parameter(s), the body eventually may again compensate to the therapy provided by the IMD, thereby again rendering the therapy provided by the IMD less beneficial. Numerous adjustments may thus be required because the body may continually compensate to the therapy. Each IMD adjustment usually requires a visit to the physician that, for many patients, is time- consuming, expensive, and generally undesirable.
BRIEF SUMMARY
[0004] The present disclosure addresses the issues noted above by reducing or preventing the body from compensating to a given therapy protocol delivered by an implanted medical device. The disclosed techniques involve a change from a first therapy protocol to a second therapy protocol based on the occurrence of an event (e.g., an elapsed time interval, user activations of the therapy, input from a physiological sensor, etc.). The first and second therapy protocols differ in terms of the on-time and off- time, but effectuate the same or a similar duty cycle. Therapy protocols that have the same duty cycle, albeit with different settings for on-time and off-time, may result in similar therapeutic benefits to the patient. The implanted medical device preferably switches from the first such therapy protocol to the second before the body has a chance to compensate for the first therapy protocol.
[0005] In at least one embodiment, a method comprises delivering an electrical signal to a nerve according to a first setting of an on-time and off-time that defines a duty cycle. The method also comprises automatically changing the first setting to a second setting of on-time and off-time in response to an event. The second setting defines a duty cycle substantially equal to the duty cycle defined by the first setting.
[0006] In another embodiment, a system comprises a pulse generator that provides an electrical signal to a nerve and a controller coupled to the pulse generator. The controller causes the pulse generator to deliver an electrical signal to a nerve according to a first setting of an on-time and off-time that defines a duty cycle. In response to a first event, the controller also causes a change from the first setting to a second setting of an on-time and off-time that defines the same or similar duty cycle as defined by the first setting. [0007] The foregoing has outlined rather broadly the features and technical advantages of the present invention in order that the detailed description of the invention that follows may be better understood. Additional features and advantages of the invention will be described hereinafter that form the subject of the claims of the invention. It should be appreciated by those skilled in the art that the conception and the specific embodiments disclosed may be readily utilized as a basis for modifying or designing other structures for carrying out the same purposes of the present invention. It should also be realized by
those skilled in the art that such equivalent constructions do not depart from the spirit and scope of the invention as set forth in the appended claims.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] For a detailed description of the preferred embodiments of the invention, reference will now be made to the accompanying drawings in which: [0009] FIGURE 1 depicts, in schematic form, an implantable medical device, in accordance with a preferred embodiment of the invention, implanted within a patient and programmable by an external programming system;
[0010] FIGURE 2 is a block diagram of the implantable medical device of Figure 1 and comprising a user input sense device; and
FIGURE 3 illustrates a flow diagram of an embodiment of a method for treating or preventing compensation in tissue stimulation therapy.
NOTATION AND NOMENCLATURE
[0011 ] Certain terms are used throughout the following description and claims to refer to particular system components. This document does not intend to distinguish between components that differ in name but not function. In the following discussion and in the claims, the terms "including" and "comprising" are used in an open-ended fashion, and thus should be interpreted to mean "including, but not limited to...". Also, the term "couple" or "couples" is intended to mean either an indirect or direct electrical connection. Thus, if a first device couples to a second device, that connection may be through a direct electrical connection, or through an indirect electrical connection via other devices and connections. The terms "substantially the same as" and "substantially equal to," when used in conjunction with an electrical signal parameter such as duty cycle, refer to two parameters differing by no more than 25%, preferably no more than 10%, and more preferably by no more than 5%.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS [0012] The present invention is susceptible to implementation in various embodiments. The disclosure of specific embodiments, including preferred embodiments, is not intended
to limit the scope of the invention as claimed unless expressly specified. In addition, persons skilled in the art will understand that the invention has broad application. Accordingly, the discussion of particular embodiments is meant only to be exemplary, and does not imply that the scope of the disclosure, including the claims, is limited to specifically disclosed embodiments.
[0013] The following description is presented largely in terms of vagus nerve stimulation ("VNS"). However, the disclosure and claims that follow are not limited to VNS, and may be applied to the delivery of an electrical signal to modulate the electrical activity of other cranial nerves such as the trigeminal and/or glossopharyngeal nerves, or to other neural tissue such as one or more brain structures of the patient, spinal nerves, and other spinal structures. Further still, other embodiments of the invention can be implemented to stimulate tissue other than nerves or neural tissue, such as cardiac tissue, muscle tissue, connective tissue, or bone tissue.
[0014] As discussed above, it is known that the body compensates or alters its response in reaction to repeated electrical signals applied to a target tissue, in the case of neurostimulation therapy applied to a nerve, without being bound by theory the body may adapt by changes to the nerve itself (which may include structural and/or functional changes), changes in one or more brain centers involved in processing electrical signals from the nerve, or both. In addressing the problem of compensation or adaptation, various embodiments of the invention comprise an implantable medical device (IMD) that alters its therapy protocol to reduce or prevent the body from compensating to the therapy. The therapy protocol provided by the IMD comprises an electrical signal applied to a target tissue, with the signal characterized by a set of parameters. The parameters comprise, in at least some embodiments, pulse frequency, pulse width, current amplitude, on-time, and off-time. One therapy protocol differs from another therapy based on differences in the underlying parameters that define each therapy protocol. The "on-time" refers to the time period during which the IMD is actively stimulating tissue and the "off- time" refers to the time period in which no stimulation is provided.
[0015] In general, the IMD described herein provides a therapy protocol in which a therapy signal (which may comprise an electrical signal, a mechanical signal such as a vibration signal, an optical signal, a chemical signal, or another type of signal) is provided
to the target tissue for an on-time and then turned off (i.e., not provided to the target tissue) during an off-time. The therapy protocol then typically repeats itself over and over until the IMD is reprogrammed, or another intervention occurs, such as a manual intervention by the patient to temporarily deliver a different protocol for a short time period.
[0016] In electrical neurostimulation therapy such as vagus nerve stimulation therapy, the electrical signal is typically applied to the nerve as a pulsed electrical signal that is defined by a plurality of parameters. These may include current amplitude, pulse width, and pulse frequency. The electrical signal as thus defined is typically applied to the nerve in a series of pulses known as a burst. The burst is defined by an on-time, e.g., 30 seconds. For pulsed electrical signals, the on-time includes interpulse periods in which no electrical pulse is being applied to the nerve. The on-time period is followed by an off- time period in which no signal is applied to the nerve. The therapy is provided by cycling between on-time and off-time periods.
[0017] The "duty" cycle" of such a therapy protocol is the percentage of time in which the signal is being provided to the target tissue, i.e., it is the ratio of on-time to the sum of on-time and off-time. For example, a 50% duty cycle means that the on-time is equal to the off-time, and the electrical signal is being provided half of the time. It is important to note that where the signal is a pulsed signal, an electrical pulse is actually applied to the nerve for a small fraction of the total on-time. For example, in a 30 second burst (i.e., 30 second on-time) having a frequency of 20 Hz and a pulse width of 0.5 milliseconds, electrical charge is actually being delivered to the nerve for only 10 milliseconds (20 Hz X 0.5 milliseconds) each second of the burst, or 1 % of the on-time. However, the entire 30 second on-time period is included in calculating the duty cycle. Thus, for pulsed electrical signals duty cycle is not the percentage of time that electrical charge is being delivered to the nerve, but the percentage of on-time to total time. In the alternative embodiment of non-pulsed signals, on the other hand, the duty cycle may equal the percentage of time that charge is delivered to the nerve.
[0018] Consistent with the foregoing, any given duty cycle can be implemented with a variety of different on-time/off-time patterns. For example, a 50% duty cycle can be implemented by a therapy protocol having an on-time of 10 seconds and an off-time of 10
seconds, as well as by a therapy protocol having an on-time of 15 seconds and an-off time of 15 seconds. Other therapy protocols having an equivalent duty cycle are obviously also available.
[0019] In accordance with some embodiments of the invention, the IMO automatically changes the on-time and off-time parameter settings periodically, without appreciably changing the duty cycle. It has been discovered that two or more therapy protocols having different on-time and off-time settings, while all other parameters remain substantially the same, including in particular duty cycle, may provide the same or similar therapeutic benefit to the patent while avoiding compensation for the signal that may reduce therapeutic benefit to the patient. Thus, in accordance with at least some embodiments, the IMD automatically changes the settings of on-time and off-time, while maintaining the duty cycle largely the same. Doing so reduces or avoids the body's tendency to compensate to the therapy protocol being delivered. That is, the body does not have a chance to compensate before the IMD changes the therapy protocol to a different therapy protocol with the same or a similar duty cycle. It has been discovered that where the duty cycle remains largely the same, the therapeutic efficacy to the patient likewise remains largely the same from one therapy to the next, but the tendency to compensate is reduced or eliminated. It is believed that such a periodically changing protocol may enable certain patients who would otherwise adapt to the therapy (thereby reducing or eliminating a therapeutic benefit) to instead maintain therapeutic efficacy. [0020] Figure 1 illustrates an implantable medical device ("IMD") 110 implanted in a patient. The IMD 110 may be representative of any of a variety of medical devices that provide a signal (e.g., an electrical, mechanical, chemical, or optical signal) to a target tissue of a patient. At least one preferred embodiment of the IMD 110 comprises a neurostimulator for applying an electrical signal to a neural structure in a patient, particularly a cranial nerve such as a vagus nerve 113. A lead assembly 116 is coupled to the IMD 110 and includes one or more electrodes, such as electrodes 112 and 114. Lead 116 has a proximal end that connects to the IMD 110 and a distal end on which the electrodes are provided. The outer housing (or "can") 129 of the IMD 110 preferably is electrically conductive and thus may also function as an electrode. The electrodes, such as electrodes 112, 114 and can 129, can be used to apply an exogenous electrical signal
to and/or sense the electrical activity of the associated tissue (e.g., the vagus nerve 113). In one embodiment, a strain relief tether 115 comprises an attachment mechanism to help secure the lead assembly 116 to the nerve 113 and to provide strain relief. An example of a suitable strain relief tether is described in U.S. Pat. No. 4,979,511, incorporated herein by reference.
[0021] Figure 1 also illustrates an external programming system 120 comprising a programming device 124 coupled to a wand 128. The programming device 124 may comprise a personal computer, handheld computer (e.g., a personal digital assistant (PDA) device), or other suitable computing device consistent with the description contained herein. Methods and apparatus for communication between the IMD 110 and an external programming system 120 are known in the art. As explained below, in one embodiment the IMD 110 includes a transceiver (such as a coil) that permits signals to be communicated wirelessly and non-invasively between the external wand 128 and the implanted IMD 110. Via the wand 128, the programming system 120 generally monitors the performance of the IMD 110 and downloads new programming parameters (e.g., on- time, off-time, pulse width, current amplitude, and pulse frequency) into the device to alter its operation as desired.
[0022] Figure 2 shows a block diagram of one embodiment of the IMD 110. As shown, the IMD 110 comprises a system that includes a battery 230, a pulse generator 232, and a controller 234. Under the control of controller 234, the pulse generator 232 generates an electrical signal to apply to a target tissue (e.g., a vagus nerve 113) in a patient. The battery 230 provides power to both the pulse generator 32 and, via the pulse generator, to the controller 234. The controller 234 generally assists, controls, and/or programs the pulse generator 232. Controller 234 preferably comprises a central processing unit (CPU) 236 such as a low-power, mixed-signal microcontroller. In general, any suitable processor can be used to implement some or all of the functionality explained herein. [0023] The CPU 236 preferably couples to one or more analog-to-digital converters (ADCs) 48 and storage 240. The storage 240 preferably comprises volatile and/or nonvolatile memory. The non-volatile memory may comprise Flash memory. The volatile memory may comprise any suitable type of random access memory (RAM). The storage 240 is used to store code that is executed by the CPU 236. Such executable code may
be loaded into the IMD 110 during manufacturing and/or may be downloaded to the IMD from the programming system 120 after implantation. The executable code may be loaded into non-volatile memory and either executed directly from the non-volatile memory or copied to the volatile memory for execution therefrom. [0024] The storage 240 or other storage (e.g., registers) in the pulse generator 232 may be used to store the parameter settings that define a therapy protocol or program. In accordance with a preferred embodiment of the invention, the IMD 110 may be programmed with a plurality of therapy protocols. The therapy protocols may be loaded into IMD 110 during manufacturing and/or downloaded to the IMD 110 from programming system 120 after implantation. The controller 234 can cause the pulse generator 232 to operate in accordance with any suitable therapy protocol from among one or more such protocols programmed into the IMD 110.
[0025] In a preferred embodiment, the IMD 110 includes a user input sensor 260 and a physiological sensor 262. Sensor 260 is used to sense an external user input such as a tap, a magnetic field, a sound, etc. Sensor 260 can be used to provide manual control of the IMD 110 by a person (e.g., the patient in which the IMD is implanted). The sensor 260 is preferably integrated within the IMD 110, but in alternative embodiments can be physically separate.
[0026] In at least one embodiment, user input sensor 260 comprises an implanted tap sensor such as an accelerometer. The tap sensor provides an electronic signal to the IMD 110 in response to a patients' physical tap or touching of the skin over the location of the implanted tap sensor. In another embodiment, the sensor 260 comprises a Reed switch that can be opened or closed by a magnet that is placed in close proximity to the IMD 110. In this embodiment, the patient may be provided with a magnet that when placed near the IMD provides a magnetic field as an input to the Reed switch, to thereby control one or more operations of the IMD 110.
[0027] Sensor 262 is sensitive to a physiological parameter of the patient in which the IMD 110 is implanted. Any number of such sensors may be included for sensing one or more physiological parameters of the patient's body functions. Physiological sensor(s) 262 may comprise any or all of the following non-limiting examples: electrodes that sense electrical activity, a pressure transducer, an acoustic element, a photonic element, a
blood pH sensor, a blood pressure sensor, a blood sugar sensor, and a body movement sensor. Accordingly, the sensors 262 that are coupled to the IMD 110 are capable of sensing one or more physiological parameters selected from the following exemplary list: an action potential in a nerve tissue, a heart parameter, a body temperature, a blood parameter (e.g., pH, pressure), food intake, gastric (e.g., stomach and/or intestinal) function, and brain activity.
[0028] Figure 3 illustrates a method 300 for reducing compensation of the patient's body to a therapy protocol performed by an IMD. In block 302, an electrical signal is delivered to a target tissue (e.g., a vagus nerve) by the IMD 110 according to a first therapy protocol having a first setting of on-time and off-time which defines a particular duty cycle. In block 304, the IMD 110 determines the occurrence of an event. In at least some embodiments, the event in block 304 comprises the expiration of a time period associated with the first on-time/off-time setting. That time period can be any fixed or programmable period of time such as 1 hour, 1 day, 1 month, etc. In other embodiments, the event may comprise a user activation parameter that is manually provided by a user to the user input sensor 260, or a physiological event that may be automatically sensed by physiological sensor 262 (Figure 2). Once the event is determined to have occurred in block 304, the IMD 110 at block 306 changes the first on-time/off-time setting to a second on-time/off- time setting while maintaining the same or a substantially similar duty cycle, and delivers to the target tissue an electrical signal according to a second therapy protocol employing the second on-time/off-time setting. As such, the therapy protocol changes in block 306 relative to the therapy protocol of block 302 but, with the duty cycle remaining the same, the therapeutic efficacy of the therapy protocol may be maintained or improved. [0029] The IMD in block 308 again determines whether an event has occurred. The event in block 308 may comprise an event of the type referred to in regard to block 304, e.g., a time period associated with the second on-time/off-time setting or a physiological event sensed by physiological sensor 262. In one embodiment, the IMD 110 continues providing an electrical signal according to the second therapy protocol and the second on- time/off-time setting for a fixed or programmable period of time that may the same as, or different from, a time period associated with the first on-time/off-time setting and the first therapy protocol. At the end of the time period for the second therapy protocol, control
reverts back to block 302 at which the process repeats. Each setting for on-time and off- time may be computed based on a prior setting.
[0030] In the embodiment of Figure 3, the IMD 110 thus provides an electrical signal to target tissue in alternating fashion in accordance with the first therapy protocol defined by a first on-time/off-time setting and then in accordance with the second therapy protocol defined by a second on-time/off-time setting. In other embodiments, more than two therapy protocols with the same or similar duty cycle can be implemented. For example, three therapy protocols can be implemented sequentially, each therapy being implemented for a specific period of time.
[0031] In accordance with some embodiments, the events occurring in blocks 304 and 308 may be other than time periods. In certain embodiments, the event may be indicated manually by a user via user input sensor 260. A user input such as a magnet may be used to signal any of a variety of user activation parameters, such as an indication of a binge/purge episode, a desire for therapy, or other parameters indicating an input from a user (e.g., the patient or a physician). In other embodiments, a physiological sensor 262 can be used to automatically detect one or more body parameters, changes of which in excess of a threshold value are the event. For example, the event may be physiological in nature such as, via a sensor 260 or 262, a bulimia patient binging and/or purging, either a single episode of binging and/or purging or binging and/or purging in excess of a predefined or programmable rate. Episodes of binging and/or purging can be detected by a variety of methods, including a manual indication by the patient or automatic detection of a body parameter such as swallowing, automatically detected gastric motility motion (e.g., stomach contractions), blood parameters such as a rapid increase in blood sugar or insulin secretion (which may be indicated either automatically via physiological sensor 262 or manually via user input sensor 260 after a conventional blood glucose test), sensed vagus nerve electrical activity, and other physiologically sensed body parameters. In some embodiments, the events in blocks 304, 308 comprise the determination that the patient has communicated (e.g., via tapping, a magnet, etc.) with a user input sensor 260 more than a threshold number of times in a given period of time. For example, a bulimia patient can manually activate the sensor 260 each time the patient feels a desire to binge or purge. If the rate at which the patient feels a need to binge and/or purge exceeds a
specified rate, the IMD 110 will automatically switch to the next scheduled therapy protocol.
[0032] In some embodiments as explained above, switching from one therapy protocol to the next can be based on time, based on a rate at which the user activates sensor 260, or based on a detection of physiological events (e.g., binging/purging). Further still, switching from one therapy protocol to the next can occur based on one or more of the expiration of defined time periods for each therapy protocol, manual activation of user input sensor 260, and/or detection of a physiological event. For example, the IMD 110 switches from one therapy protocol to another at defined time intervals, but one therapy protocol can be terminated prematurely in favor of the next scheduled therapy protocol if the user activates the sensor device 260 at a rate greater than a threshold rate. [0033] In accordance with at least some embodiments, user input sensor 260 can also be used by a person (e.g., the patient in which the IMD 110 is implanted) to provide additional information to the IMD 110. In some embodiments, the IMD's controller 234 determines an action to be performed according to the number of user activations of the user input sensor 260. For example, a patient may activate the user input sensor device 260 once to signify the occurrence of a physiological or psychological event (e.g., the desire to binge or purge). The IMD 110 may then record in, for example, storage 240 that such an event has occurred. Such information can be used for a variety of purposes such as verifying the accuracy of what a bulimic patient reports to a healthcare provider regarding his or her desire to binge and purge.
[0034] In at least some embodiments, user activations of the user input sensor 260 can be performed to cause the IMD 110 to deliver an immediate stimulation. The number of user activations may encode the type of stimulation to be delivered. For example, three activations of sensor 260 in quick succession may cause the IMD 110 to deliver a larger stimulation level (e.g., greater current amplitude) than two activations of sensor 260 in quick succession.
[0035] Although the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations may be made herein without departing from the spirit and scope of the invention as defined by the appended claims.
Claims
1. A method of treating a patient, comprising: delivering an electrical signal to a nerve according to a first setting of an on-time and off -time that defines a duty cycle; and automatically changing said first setting to a second setting of on-time and off-time in response to a first event, wherein said second setting defines a duty cycle substantially equal to the duty cycle defined by said first setting.
2. The method of claim 1, wherein (b) further comprises sensing an occurrence of said first event following changing to said second setting and repeating (a) and (b).
3. The method of claim 1 wherein said first event comprises an expiration of a defined time period.
4. The method of claim 1, wherein said first event comprises a physiological or psychological event.
5. The method of claim 1 , wherein said first event comprises a sensed user input.
6. The method of claim 1 , further comprising automatically changing said second setting to a third setting of on-time and off-time in response to a second event, wherein
, said third setting defines a duty cycle substantially equal to the duty cycle defined by said first and second settings.
7. A system, comprising: at least one electrode coupled to a nerve; a pulse generator coupled to said at least one electrode, wherein said pulse generator provides an electrical signal to a nerve using said at least one electrode; and a controller coupled to said pulse generator, wherein said controller causes sad pulse generator to deliver said electrical signal to a nerve according to a first setting of an on-time and off-time that defines a first duty cycle and, in response to a first event, causes a change from said first setting to a second setting of an on-time and off-time that defines a second duty cycle that is substantially equal to the first duty cycle.
8. The system of claim 7, further comprising a user input sensor coupled to the controller, wherein said user input sensor senses a manual control input to control an operation of the pulse generator.
9. The system of claim 8, wherein said first event comprises a user activation parameter of said sensor in excess of an activation parameter threshold.
10. The system of claim 7, further comprising a physiological sensor coupled to the controller to control, at least in part, changing from the first setting to the second setting.
11. The system of claim 7 wherein said first event comprises an expiration of a defined time period.
12. The system of claim 11 further comprising a user input sensor capable of sensing a user input signal, and wherein said first event comprises at least one of an expiration of a defined time period and a sensed user input signal.
13. A method of treating a patient having a medical condition, comprising: applying to a vagus nerve of the patient a first electrical signal defined by a first plurality of parameters comprising a first on-time and a first off-time defining a first duty cycle; determining the occurrence of a first event and, in response to said first event ceasing said step of applying said first electrical signal to said vagus nerve, and applying to said vagus nerve a second electrical signal defined by a second plurality of parameters comprising a second on-time and a second off-time defining a second duty cycle substantially the same as said first duty cycle.
14. The method of claim 13 wherein said first plurality of parameters comprises at least one of a first current magnitude, a first frequency, and a first pulse width, and said second plurality of parameters comprises at least one of a second current magnitude, a second frequency, and a second pulse width.
15. The method of claim 14 wherein at least one of said second current magnitude, said second frequency, and said second pulse width is the same as a respective one of said first current magnitude, said first frequency, and said first pulse width.
16. The method of claim 13 wherein said first event first is selected from the group consisting of the expiration of a defined time period, a physiological event, a psychological event, and a sensed user input.
17. The method of claim 13 further comprising: detecting the occurrence of a second event, and in response to said second event ceasing said step of applying said second electrical signal to said vagus nerve, and applying said first electrical signal to said vagus nerve.
18. The method of claim 13 further comprising: detecting the occurrence of a second event, and in response to said second event ceasing said step of applying said second electrical signal to said vagus nerve, and applying to said vagus nerve a third electrical signal defined by a third plurality of parameters comprising a third on-time and a third off-time characterized by a third duty cycle substantially the same as said first duty cycle.
19. The method of claim 13, wherein said second duty cycle differs from said first duty cycle by no more than 25%
20. The method of claim 13, wherein said second duty cycle differs from said first duty cycle by no more than 10%.
21. The method of claim 13, wherein said second duty cycle differs from said first duty cycle by no more than 5%.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT07755837T ATE512692T1 (en) | 2006-04-28 | 2007-04-23 | DEVICE FOR COMPENSATION REDUCTION IN TISSUE STIMULATION THERAPY |
EP07755837A EP2019714B1 (en) | 2006-04-28 | 2007-04-23 | Apparatus for compensation reduction in tissue stimulation therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/414,391 | 2006-04-28 | ||
US11/414,391 US7962220B2 (en) | 2006-04-28 | 2006-04-28 | Compensation reduction in tissue stimulation therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007127150A1 true WO2007127150A1 (en) | 2007-11-08 |
Family
ID=38445827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/009723 WO2007127150A1 (en) | 2006-04-28 | 2007-04-23 | Compensation reduction in tissue stimulation therapy |
Country Status (4)
Country | Link |
---|---|
US (1) | US7962220B2 (en) |
EP (1) | EP2019714B1 (en) |
AT (1) | ATE512692T1 (en) |
WO (1) | WO2007127150A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2977078A1 (en) | 2014-07-23 | 2016-01-27 | Sorin CRM SAS | Active implantable medical device for therapy by vagus nerve stimulation, with dynamically adjusting stimulation periods |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
US11207518B2 (en) * | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
EP2026874B1 (en) | 2006-03-29 | 2015-05-20 | Dignity Health | Vagus nerve stimulation system |
US8391970B2 (en) * | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
US10561845B2 (en) * | 2007-09-24 | 2020-02-18 | Medtronic, Inc. | Therapy adjustment based on patient event indication |
US8165669B2 (en) | 2007-12-05 | 2012-04-24 | The Invention Science Fund I, Llc | System for magnetic modulation of neural conduction |
US8165668B2 (en) * | 2007-12-05 | 2012-04-24 | The Invention Science Fund I, Llc | Method for magnetic modulation of neural conduction |
US8989858B2 (en) * | 2007-12-05 | 2015-03-24 | The Invention Science Fund I, Llc | Implant system for chemical modulation of neural activity |
US8180446B2 (en) | 2007-12-05 | 2012-05-15 | The Invention Science Fund I, Llc | Method and system for cyclical neural modulation based on activity state |
US8180447B2 (en) | 2007-12-05 | 2012-05-15 | The Invention Science Fund I, Llc | Method for reversible chemical modulation of neural activity |
US8195287B2 (en) | 2007-12-05 | 2012-06-05 | The Invention Science Fund I, Llc | Method for electrical modulation of neural conduction |
US8170658B2 (en) | 2007-12-05 | 2012-05-01 | The Invention Science Fund I, Llc | System for electrical modulation of neural conduction |
US8170659B2 (en) | 2007-12-05 | 2012-05-01 | The Invention Science Fund I, Llc | Method for thermal modulation of neural activity |
US20090149799A1 (en) * | 2007-12-05 | 2009-06-11 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Method for chemical modulation of neural activity |
WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
EP2313148B1 (en) | 2008-07-30 | 2013-08-21 | Ecole Polytechnique Fédérale de Lausanne | Apparatus for optimized stimulation of a neurological target |
CA2743575C (en) | 2008-11-12 | 2017-01-31 | Ecole Polytechnique Federale De Lausanne | Microfabricated neurostimulation device |
AU2009316801C1 (en) | 2008-11-18 | 2015-12-24 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflammatory stimulation |
WO2010111324A1 (en) * | 2009-03-27 | 2010-09-30 | Medtronic, Inc. | Conditional electrical stimulation in response to user input for pelvic health |
US9561366B2 (en) | 2009-03-27 | 2017-02-07 | Medtronic, Inc. | Conditional electrical stimulation |
US8788034B2 (en) | 2011-05-09 | 2014-07-22 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8886339B2 (en) | 2009-06-09 | 2014-11-11 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
US8996116B2 (en) * | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US20120095524A1 (en) * | 2009-06-30 | 2012-04-19 | The Bionics Institute Of Australia | Method of counteracting seizures |
WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
CA2782710C (en) | 2009-12-01 | 2019-01-22 | Ecole Polytechnique Federale De Lausanne | Microfabricated neurostimulation device and methods of making and using the same |
EP3636314B1 (en) | 2009-12-23 | 2021-09-08 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
EP2552536B1 (en) | 2010-04-01 | 2016-06-08 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Device for interacting with neurological tissue |
US8874229B2 (en) * | 2010-04-28 | 2014-10-28 | Cyberonics, Inc. | Delivering scheduled and unscheduled therapy without detriment to battery life or accuracy of longevity predictions |
WO2013111137A2 (en) | 2012-01-26 | 2013-08-01 | Rainbow Medical Ltd. | Wireless neurqstimulatqrs |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
WO2014087337A1 (en) | 2012-12-06 | 2014-06-12 | Bluewind Medical Ltd. | Delivery of implantable neurostimulators |
US11311718B2 (en) | 2014-05-16 | 2022-04-26 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
CN106455985B (en) | 2014-05-16 | 2019-09-17 | 阿莱瓦神经治疗股份有限公司 | With the device and production and preparation method thereof of nerve fiber interaction |
US9934631B2 (en) * | 2014-08-18 | 2018-04-03 | Location Labs, Inc. | Bio-implantable identification device and corresponding operating methods |
US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
US9403011B2 (en) | 2014-08-27 | 2016-08-02 | Aleva Neurotherapeutics | Leadless neurostimulator |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US10376145B2 (en) | 2015-02-24 | 2019-08-13 | Elira, Inc. | Systems and methods for enabling a patient to achieve a weight loss objective using an electrical dermal patch |
US10864367B2 (en) | 2015-02-24 | 2020-12-15 | Elira, Inc. | Methods for using an electrical dermal patch in a manner that reduces adverse patient reactions |
US10765863B2 (en) | 2015-02-24 | 2020-09-08 | Elira, Inc. | Systems and methods for using a transcutaneous electrical stimulation device to deliver titrated therapy |
CN108271363B (en) | 2015-02-24 | 2022-08-09 | 伊莱拉股份有限公司 | System and method for achieving appetite regulation and/or improving dietary compliance using electrode patches |
US9956393B2 (en) | 2015-02-24 | 2018-05-01 | Elira, Inc. | Systems for increasing a delay in the gastric emptying time for a patient using a transcutaneous electro-dermal patch |
US10335302B2 (en) | 2015-02-24 | 2019-07-02 | Elira, Inc. | Systems and methods for using transcutaneous electrical stimulation to enable dietary interventions |
US10105540B2 (en) | 2015-11-09 | 2018-10-23 | Bluewind Medical Ltd. | Optimization of application of current |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
EP3405255A4 (en) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
US10695569B2 (en) | 2016-01-20 | 2020-06-30 | Setpoint Medical Corporation | Control of vagal stimulation |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
WO2017134587A1 (en) | 2016-02-02 | 2017-08-10 | Aleva Neurotherapeutics, Sa | Treatment of autoimmune diseases with deep brain stimulation |
US10124178B2 (en) | 2016-11-23 | 2018-11-13 | Bluewind Medical Ltd. | Implant and delivery tool therefor |
US20180353764A1 (en) | 2017-06-13 | 2018-12-13 | Bluewind Medical Ltd. | Antenna configuration |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US10702692B2 (en) | 2018-03-02 | 2020-07-07 | Aleva Neurotherapeutics | Neurostimulation device |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
EP3849410A4 (en) | 2018-09-14 | 2022-11-02 | Neuroenhancement Lab, LLC | System and method of improving sleep |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
EP4153053A1 (en) | 2020-05-21 | 2023-03-29 | The Feinstein Institutes for Medical Research | Systems and methods for vagus nerve stimulation |
US11400299B1 (en) | 2021-09-14 | 2022-08-02 | Rainbow Medical Ltd. | Flexible antenna for stimulator |
WO2023192636A1 (en) * | 2022-03-31 | 2023-10-05 | The Alfred E. Mann Foundation For Scientific Research | Systems and methods for vagus nerve stimulation |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4979511A (en) | 1989-11-03 | 1990-12-25 | Cyberonics, Inc. | Strain relief tether for implantable electrode |
WO2004064918A1 (en) * | 2003-01-14 | 2004-08-05 | Department Of Veterans Affairs, Office Of General Counsel | Cervical wagal stimulation induced weight loss |
US20050049649A1 (en) * | 2002-10-21 | 2005-03-03 | The Cleveland Clinic Foundation | Electrical stimulation of the brain |
US20060015153A1 (en) * | 2004-07-15 | 2006-01-19 | Gliner Bradford E | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
Family Cites Families (387)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3760812A (en) | 1971-03-19 | 1973-09-25 | Univ Minnesota | Implantable spiral wound stimulation electrodes |
US3796221A (en) | 1971-07-07 | 1974-03-12 | N Hagfors | Apparatus for delivering electrical stimulation energy to body-implanted apparatus with signal-receiving means |
US4107469A (en) | 1977-02-17 | 1978-08-15 | Rockwell International Corporation | Multiplex/demultiplex apparatus |
JPS54119792A (en) | 1978-03-03 | 1979-09-17 | Iriyou Kougaku Kenkiyuushiyo K | Electric stimulation device for removing pain |
IT1118131B (en) | 1978-07-20 | 1986-02-24 | Medtronic Inc | IMPROVEMENT IN MULTI-MODE CARDIAC PACEMAKERS ADAPTABLE IMPLANTABLE |
US4431000A (en) | 1978-11-29 | 1984-02-14 | Gatron Corporation | Transcutaneous nerve stimulator with pseusorandom pulse generator |
US4305402A (en) | 1979-06-29 | 1981-12-15 | Katims Jefferson J | Method for transcutaneous electrical stimulation |
US4503863A (en) | 1979-06-29 | 1985-03-12 | Katims Jefferson J | Method and apparatus for transcutaneous electrical stimulation |
US4424812A (en) | 1980-10-09 | 1984-01-10 | Cordis Corporation | Implantable externally programmable microprocessor-controlled tissue stimulator |
US4612934A (en) | 1981-06-30 | 1986-09-23 | Borkan William N | Non-invasive multiprogrammable tissue stimulator |
US4793353A (en) | 1981-06-30 | 1988-12-27 | Borkan William N | Non-invasive multiprogrammable tissue stimulator and method |
US4459989A (en) | 1981-06-30 | 1984-07-17 | Neuromed, Inc. | Non-invasive multiprogrammable tissue stimulator and methods for use |
US4606349A (en) | 1981-08-10 | 1986-08-19 | Cordis Corporation | Implantable cardiac pacer having dual frequency programming and bipolar/unipolar lead programmability |
US4625308A (en) | 1982-11-30 | 1986-11-25 | American Satellite Company | All digital IDMA dynamic channel allocated satellite communications system and method |
CA1215128A (en) | 1982-12-08 | 1986-12-09 | Pedro Molina-Negro | Electric nerve stimulator device |
US4702254A (en) | 1983-09-14 | 1987-10-27 | Jacob Zabara | Neurocybernetic prosthesis |
US4867164A (en) | 1983-09-14 | 1989-09-19 | Jacob Zabara | Neurocybernetic prosthesis |
US5025807A (en) | 1983-09-14 | 1991-06-25 | Jacob Zabara | Neurocybernetic prosthesis |
US4577316A (en) | 1984-02-13 | 1986-03-18 | Rca Corporation | Synchronization system for a regenerative subtransponder satellite communication system |
US4590946A (en) | 1984-06-14 | 1986-05-27 | Biomed Concepts, Inc. | Surgically implantable electrode for nerve bundles |
US4573481A (en) | 1984-06-25 | 1986-03-04 | Huntington Institute Of Applied Research | Implantable electrode array |
US4628942A (en) | 1984-10-11 | 1986-12-16 | Case Western Reserve University | Asymmetric shielded two electrode cuff |
US4649936A (en) | 1984-10-11 | 1987-03-17 | Case Western Reserve University | Asymmetric single electrode cuff for generation of unidirectionally propagating action potentials for collision blocking |
US4608985A (en) | 1984-10-11 | 1986-09-02 | Case Western Reserve University | Antidromic pulse generating wave form for collision blocking |
US4592339A (en) | 1985-06-12 | 1986-06-03 | Mentor Corporation | Gastric banding device |
GB8813518D0 (en) | 1988-06-08 | 1988-07-13 | Dunlop Ltd | Improvements in multi-disc brakes |
US4949721A (en) | 1988-08-11 | 1990-08-21 | Omron Tateisi Electronics Co. | Transcutaneous electric nerve stimulater |
US4920979A (en) | 1988-10-12 | 1990-05-01 | Huntington Medical Research Institute | Bidirectional helical electrode for nerve stimulation |
EP0387363B1 (en) | 1989-03-13 | 1994-06-01 | Pacesetter AB | Implantable stimulator whose intensity of stimulation of a physiologic event of living beings is adapted to their physical actvity |
US5210854A (en) | 1989-06-14 | 1993-05-11 | Digital Equipment Corporation | System for updating program stored in eeprom by storing new version into new location and updating second transfer vector to contain starting address of new version |
US5522865A (en) | 1989-09-22 | 1996-06-04 | Alfred E. Mann Foundation For Scientific Research | Voltage/current control system for a human tissue stimulator |
US5154172A (en) | 1989-11-13 | 1992-10-13 | Cyberonics, Inc. | Constant current sources with programmable voltage source |
US5186170A (en) | 1989-11-13 | 1993-02-16 | Cyberonics, Inc. | Simultaneous radio frequency and magnetic field microprocessor reset circuit |
US5235980A (en) | 1989-11-13 | 1993-08-17 | Cyberonics, Inc. | Implanted apparatus disabling switching regulator operation to allow radio frequency signal reception |
US5179950A (en) | 1989-11-13 | 1993-01-19 | Cyberonics, Inc. | Implanted apparatus having micro processor controlled current and voltage sources with reduced voltage levels when not providing stimulation |
US5188104A (en) | 1991-02-01 | 1993-02-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5263480A (en) | 1991-02-01 | 1993-11-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
US5269303A (en) | 1991-02-22 | 1993-12-14 | Cyberonics, Inc. | Treatment of dementia by nerve stimulation |
US5299569A (en) | 1991-05-03 | 1994-04-05 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by nerve stimulation |
US5215086A (en) | 1991-05-03 | 1993-06-01 | Cyberonics, Inc. | Therapeutic treatment of migraine symptoms by stimulation |
US5205285A (en) | 1991-06-14 | 1993-04-27 | Cyberonics, Inc. | Voice suppression of vagal stimulation |
US5222494A (en) | 1991-07-31 | 1993-06-29 | Cyberonics, Inc. | Implantable tissue stimulator output stabilization system |
AU2399892A (en) | 1991-08-09 | 1993-03-02 | Cyberonics, Inc. | Treatment of anxiety disorders by nerve stimulation |
US5231988A (en) | 1991-08-09 | 1993-08-03 | Cyberonics, Inc. | Treatment of endocrine disorders by nerve stimulation |
US5354320A (en) | 1991-09-12 | 1994-10-11 | Biotronik Mess- Und Therapiegerate Gmbh & Co., Ingenieurburo Berlin | Neurostimulator for production of periodic stimulation pulses |
IT1259358B (en) | 1992-03-26 | 1996-03-12 | Sorin Biomedica Spa | IMPLANTABLE DEVICE FOR DETECTION AND CONTROL OF THE SYMPATHIC-VAGAL TONE |
US5330507A (en) | 1992-04-24 | 1994-07-19 | Medtronic, Inc. | Implantable electrical vagal stimulation for prevention or interruption of life threatening arrhythmias |
GB9211085D0 (en) | 1992-05-23 | 1992-07-08 | Tippey Keith E | Electrical stimulation |
IT1260485B (en) | 1992-05-29 | 1996-04-09 | PROCEDURE AND DEVICE FOR THE TREATMENT OF THE OBESITY OF A PATIENT | |
US5330515A (en) * | 1992-06-17 | 1994-07-19 | Cyberonics, Inc. | Treatment of pain by vagal afferent stimulation |
JPH07504597A (en) | 1992-06-30 | 1995-05-25 | メドトロニック インコーポレーテッド | Electrical medical stimulators and electrical stimulation methods |
DE4404140B4 (en) | 1993-02-10 | 2005-11-10 | Siemens Ag | Use of a pressure pulse source pulse-like shock waves and provided for such use pressure pulse source |
US5411540A (en) | 1993-06-03 | 1995-05-02 | Massachusetts Institute Of Technology | Method and apparatus for preferential neuron stimulation |
US5411531A (en) | 1993-09-23 | 1995-05-02 | Medtronic, Inc. | Method and apparatus for control of A-V interval |
EP0688578B1 (en) | 1994-06-24 | 1999-11-10 | Pacesetter AB | Arrhythmia detector |
US5522862A (en) | 1994-09-21 | 1996-06-04 | Medtronic, Inc. | Method and apparatus for treating obstructive sleep apnea |
US5540734A (en) | 1994-09-28 | 1996-07-30 | Zabara; Jacob | Cranial nerve stimulation treatments using neurocybernetic prosthesis |
US5647379A (en) | 1994-11-22 | 1997-07-15 | Ventritex, Inc. | Correlator based electromagnetic interference responsive control system useful in medical devices |
US6425852B1 (en) | 1994-11-28 | 2002-07-30 | Emory University | Apparatus and method for transcranial magnetic brain stimulation, including the treatment of depression and the localization and characterization of speech arrest |
US6132361A (en) | 1994-11-28 | 2000-10-17 | Neotonus, Inc. | Transcranial brain stimulation |
US5571150A (en) | 1994-12-19 | 1996-11-05 | Cyberonics, Inc. | Treatment of patients in coma by nerve stimulation |
US5601617A (en) | 1995-04-26 | 1997-02-11 | Advanced Bionics Corporation | Multichannel cochlear prosthesis with flexible control of stimulus waveforms |
US6219580B1 (en) | 1995-04-26 | 2001-04-17 | Advanced Bionics Corporation | Multichannel cochlear prosthesis with flexible control of stimulus waveforms |
US5540730A (en) | 1995-06-06 | 1996-07-30 | Cyberonics, Inc. | Treatment of motility disorders by nerve stimulation |
US5707400A (en) | 1995-09-19 | 1998-01-13 | Cyberonics, Inc. | Treating refractory hypertension by nerve stimulation |
US5700282A (en) | 1995-10-13 | 1997-12-23 | Zabara; Jacob | Heart rhythm stabilization using a neurocybernetic prosthesis |
US6944501B1 (en) | 2000-04-05 | 2005-09-13 | Neurospace, Inc. | Neurostimulator involving stimulation strategies and process for using it |
US6480743B1 (en) | 2000-04-05 | 2002-11-12 | Neuropace, Inc. | System and method for adaptive brain stimulation |
US5755750A (en) | 1995-11-13 | 1998-05-26 | University Of Florida | Method and apparatus for selectively inhibiting activity in nerve fibers |
US5995868A (en) | 1996-01-23 | 1999-11-30 | University Of Kansas | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
US6463328B1 (en) | 1996-02-02 | 2002-10-08 | Michael Sasha John | Adaptive brain stimulation method and system |
US5611350A (en) | 1996-02-08 | 1997-03-18 | John; Michael S. | Method and apparatus for facilitating recovery of patients in deep coma |
US5651378A (en) | 1996-02-20 | 1997-07-29 | Cardiothoracic Systems, Inc. | Method of using vagal nerve stimulation in surgery |
US6051017A (en) | 1996-02-20 | 2000-04-18 | Advanced Bionics Corporation | Implantable microstimulator and systems employing the same |
US5913876A (en) | 1996-02-20 | 1999-06-22 | Cardiothoracic Systems, Inc. | Method and apparatus for using vagus nerve stimulation in surgery |
US5690681A (en) | 1996-03-29 | 1997-11-25 | Purdue Research Foundation | Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation |
UA48221C2 (en) | 1996-04-01 | 2002-08-15 | Валєрій Івановіч Кобозєв | Electrical gastro-intestinal tract stimulator |
US5702429A (en) | 1996-04-04 | 1997-12-30 | Medtronic, Inc. | Neural stimulation techniques with feedback |
US6532388B1 (en) | 1996-04-30 | 2003-03-11 | Medtronic, Inc. | Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure |
US6628987B1 (en) | 2000-09-26 | 2003-09-30 | Medtronic, Inc. | Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia |
US6006134A (en) | 1998-04-30 | 1999-12-21 | Medtronic, Inc. | Method and device for electronically controlling the beating of a heart using venous electrical stimulation of nerve fibers |
US5690691A (en) | 1996-05-08 | 1997-11-25 | The Center For Innovative Technology | Gastro-intestinal pacemaker having phased multi-point stimulation |
AU3304997A (en) | 1996-05-31 | 1998-01-05 | Southern Illinois University | Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation |
US6609031B1 (en) | 1996-06-07 | 2003-08-19 | Advanced Neuromodulation Systems, Inc. | Multiprogrammable tissue stimulator and method |
US6246912B1 (en) | 1996-06-27 | 2001-06-12 | Sherwood Services Ag | Modulated high frequency tissue modification |
US5800474A (en) | 1996-11-01 | 1998-09-01 | Medtronic, Inc. | Method of controlling epilepsy by brain stimulation |
US5690688A (en) | 1996-11-12 | 1997-11-25 | Pacesetter Ab | Medical therapy apparatus which administers therapy adjusted to follow natural variability of the physiological function being controlled |
AR010696A1 (en) | 1996-12-12 | 2000-06-28 | Sasol Tech Pty Ltd | A METHOD FOR THE ELIMINATION OF CARBON DIOXIDE FROM A PROCESS GAS |
US7630757B2 (en) | 1997-01-06 | 2009-12-08 | Flint Hills Scientific Llc | System for the prediction, rapid detection, warning, prevention, or control of changes in activity states in the brain of a subject |
US6026326A (en) | 1997-01-13 | 2000-02-15 | Medtronic, Inc. | Apparatus and method for treating chronic constipation |
EP1666087A3 (en) | 1997-02-26 | 2009-04-29 | The Alfred E Mann Foundation for Scientific Research | Battery-powered patient implantable device |
US5792212A (en) | 1997-03-07 | 1998-08-11 | Medtronic, Inc. | Nerve evoked potential measurement system using chaotic sequences for noise rejection |
US5861014A (en) | 1997-04-30 | 1999-01-19 | Medtronic, Inc. | Method and apparatus for sensing a stimulating gastrointestinal tract on-demand |
US5836994A (en) | 1997-04-30 | 1998-11-17 | Medtronic, Inc. | Method and apparatus for electrical stimulation of the gastrointestinal tract |
IT1292016B1 (en) | 1997-05-28 | 1999-01-25 | Valerio Cigaina | IMPLANT DEVICE PARTICULARLY FOR ELECTROSTIMULATION AND / OR ELECTRO-REGISTRATION OF ENDOABDOMINAL VISCERS |
WO1999007354A2 (en) | 1997-08-08 | 1999-02-18 | Duke University | Compositions, apparatus and methods for facilitating surgical procedures |
US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
US6141590A (en) | 1997-09-25 | 2000-10-31 | Medtronic, Inc. | System and method for respiration-modulated pacing |
US6409674B1 (en) | 1998-09-24 | 2002-06-25 | Data Sciences International, Inc. | Implantable sensor with wireless communication |
US5941906A (en) | 1997-10-15 | 1999-08-24 | Medtronic, Inc. | Implantable, modular tissue stimulator |
US6016449A (en) | 1997-10-27 | 2000-01-18 | Neuropace, Inc. | System for treatment of neurological disorders |
US6459936B2 (en) | 1997-10-27 | 2002-10-01 | Neuropace, Inc. | Methods for responsively treating neurological disorders |
US6104955A (en) | 1997-12-15 | 2000-08-15 | Medtronic, Inc. | Method and apparatus for electrical stimulation of the gastrointestinal tract |
US6078838A (en) | 1998-02-13 | 2000-06-20 | University Of Iowa Research Foundation | Pseudospontaneous neural stimulation system and method |
US6221908B1 (en) | 1998-03-12 | 2001-04-24 | Scientific Learning Corporation | System for stimulating brain plasticity |
US6374140B1 (en) | 1998-04-30 | 2002-04-16 | Medtronic, Inc. | Method and apparatus for treating seizure disorders by stimulating the olfactory senses |
US5928272A (en) | 1998-05-02 | 1999-07-27 | Cyberonics, Inc. | Automatic activation of a neurostimulator device using a detection algorithm based on cardiac activity |
US6463327B1 (en) | 1998-06-11 | 2002-10-08 | Cprx Llc | Stimulatory device and methods to electrically stimulate the phrenic nerve |
US7853329B2 (en) | 1998-08-05 | 2010-12-14 | Neurovista Corporation | Monitoring efficacy of neural modulation therapy |
US7747325B2 (en) | 1998-08-05 | 2010-06-29 | Neurovista Corporation | Systems and methods for monitoring a patient's neurological disease state |
US6366813B1 (en) | 1998-08-05 | 2002-04-02 | Dilorenzo Daniel J. | Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease |
US7242984B2 (en) | 1998-08-05 | 2007-07-10 | Neurovista Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US9375573B2 (en) | 1998-08-05 | 2016-06-28 | Cyberonics, Inc. | Systems and methods for monitoring a patient's neurological disease state |
US8762065B2 (en) | 1998-08-05 | 2014-06-24 | Cyberonics, Inc. | Closed-loop feedback-driven neuromodulation |
US7231254B2 (en) | 1998-08-05 | 2007-06-12 | Bioneuronics Corporation | Closed-loop feedback-driven neuromodulation |
US7209787B2 (en) | 1998-08-05 | 2007-04-24 | Bioneuronics Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US6249704B1 (en) | 1998-08-11 | 2001-06-19 | Advanced Bionics Corporation | Low voltage stimulation to elicit stochastic response patterns that enhance the effectiveness of a cochlear implant |
US6615081B1 (en) | 1998-10-26 | 2003-09-02 | Birinder R. Boveja | Apparatus and method for adjunct (add-on) treatment of diabetes by neuromodulation with an external stimulator |
US6564102B1 (en) | 1998-10-26 | 2003-05-13 | Birinder R. Boveja | Apparatus and method for adjunct (add-on) treatment of coma and traumatic brain injury with neuromodulation using an external stimulator |
US6269270B1 (en) | 1998-10-26 | 2001-07-31 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy of Dementia and Alzheimer's disease utilizing an implantable lead and external stimulator |
US6505074B2 (en) | 1998-10-26 | 2003-01-07 | Birinder R. Boveja | Method and apparatus for electrical stimulation adjunct (add-on) treatment of urinary incontinence and urological disorders using an external stimulator |
US6356788B2 (en) | 1998-10-26 | 2002-03-12 | Birinder Bob Boveja | Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator |
US6366814B1 (en) | 1998-10-26 | 2002-04-02 | Birinder R. Boveja | External stimulator for adjunct (add-on) treatment for neurological, neuropsychiatric, and urological disorders |
US6611715B1 (en) | 1998-10-26 | 2003-08-26 | Birinder R. Boveja | Apparatus and method for neuromodulation therapy for obesity and compulsive eating disorders using an implantable lead-receiver and an external stimulator |
US6668191B1 (en) | 1998-10-26 | 2003-12-23 | Birinder R. Boveja | Apparatus and method for electrical stimulation adjunct (add-on) therapy of atrial fibrillation, inappropriate sinus tachycardia, and refractory hypertension with an external stimulator |
US6253109B1 (en) | 1998-11-05 | 2001-06-26 | Medtronic Inc. | System for optimized brain stimulation |
US6161044A (en) | 1998-11-23 | 2000-12-12 | Synaptic Corporation | Method and apparatus for treating chronic pain syndromes, tremor, dementia and related disorders and for inducing electroanesthesia using high frequency, high intensity transcutaneous electrical nerve stimulation |
US6155267A (en) | 1998-12-31 | 2000-12-05 | Medtronic, Inc. | Implantable medical device monitoring method and system regarding same |
US6324421B1 (en) | 1999-03-29 | 2001-11-27 | Medtronic, Inc. | Axis shift analysis of electrocardiogram signal parameters especially applicable for multivector analysis by implantable medical devices, and use of same |
US6115628A (en) | 1999-03-29 | 2000-09-05 | Medtronic, Inc. | Method and apparatus for filtering electrocardiogram (ECG) signals to remove bad cycle information and for use of physiologic signals determined from said filtered ECG signals |
US6684104B2 (en) | 1999-04-14 | 2004-01-27 | Transneuronix, Inc. | Gastric stimulator apparatus and method for installing |
US6895278B1 (en) | 1999-04-14 | 2005-05-17 | Transneuronix, Inc. | Gastric stimulator apparatus and method for use |
US6190324B1 (en) | 1999-04-28 | 2001-02-20 | Medtronic, Inc. | Implantable medical device for tracking patient cardiac status |
US6353762B1 (en) | 1999-04-30 | 2002-03-05 | Medtronic, Inc. | Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve |
US6341236B1 (en) | 1999-04-30 | 2002-01-22 | Ivan Osorio | Vagal nerve stimulation techniques for treatment of epileptic seizures |
US6579280B1 (en) | 1999-04-30 | 2003-06-17 | Medtronic, Inc. | Generic multi-step therapeutic treatment protocol |
US6312378B1 (en) | 1999-06-03 | 2001-11-06 | Cardiac Intelligence Corporation | System and method for automated collection and analysis of patient information retrieved from an implantable medical device for remote patient care |
US6167311A (en) | 1999-06-14 | 2000-12-26 | Electro Core Techniques, Llc | Method of treating psychological disorders by brain stimulation within the thalamus |
US7454359B2 (en) | 1999-06-23 | 2008-11-18 | Visicu, Inc. | System and method for displaying a health status of hospitalized patients |
US7991625B2 (en) | 1999-06-23 | 2011-08-02 | Koninklijke Philips Electronics N.V. | System for providing expert care to a basic care medical facility from a remote location |
US6587719B1 (en) | 1999-07-01 | 2003-07-01 | Cyberonics, Inc. | Treatment of obesity by bilateral vagus nerve stimulation |
US6188929B1 (en) | 1999-07-15 | 2001-02-13 | Joseph Giordano | Sequentially generated multi-parameter bio-electric delivery system and method |
US6298271B1 (en) | 1999-07-19 | 2001-10-02 | Medtronic, Inc. | Medical system having improved telemetry |
US6820019B1 (en) | 1999-07-31 | 2004-11-16 | Medtronic, Inc. | Device and method for determining and communicating the remaining life of a battery in an implantable neurological tissue stimulating device |
US6304775B1 (en) | 1999-09-22 | 2001-10-16 | Leonidas D. Iasemidis | Seizure warning and prediction |
US6308102B1 (en) | 1999-09-29 | 2001-10-23 | Stimsoft, Inc. | Patient interactive neurostimulation system and method |
US6381496B1 (en) | 1999-10-01 | 2002-04-30 | Advanced Bionics Corporation | Parameter context switching for an implanted device |
US6560486B1 (en) | 1999-10-12 | 2003-05-06 | Ivan Osorio | Bi-directional cerebral interface system |
US6473644B1 (en) | 1999-10-13 | 2002-10-29 | Cyberonics, Inc. | Method to enhance cardiac capillary growth in heart failure patients |
US6764498B2 (en) | 1999-12-09 | 2004-07-20 | Hans Alois Mische | Methods and devices for treatment of neurological disorders |
US6853862B1 (en) | 1999-12-03 | 2005-02-08 | Medtronic, Inc. | Gastroelectric stimulation for influencing pancreatic secretions |
US6587724B2 (en) | 1999-12-17 | 2003-07-01 | Advanced Bionics Corporation | Magnitude programming for implantable electrical stimulator |
US20050240246A1 (en) | 1999-12-24 | 2005-10-27 | Medtronic, Inc. | Large-scale processing loop for implantable medical devices |
US6438423B1 (en) | 2000-01-20 | 2002-08-20 | Electrocore Technique, Llc | Method of treating complex regional pain syndromes by electrical stimulation of the sympathetic nerve chain |
US6885888B2 (en) | 2000-01-20 | 2005-04-26 | The Cleveland Clinic Foundation | Electrical stimulation of the sympathetic nerve chain |
US20060085046A1 (en) | 2000-01-20 | 2006-04-20 | Ali Rezai | Methods of treating medical conditions by transvascular neuromodulation of the autonomic nervous system |
US6600953B2 (en) | 2000-12-11 | 2003-07-29 | Impulse Dynamics N.V. | Acute and chronic electrical signal therapy for obesity |
DE10002932A1 (en) | 2000-01-25 | 2001-07-26 | Biotronik Mess & Therapieg | Medical device implant |
US6609030B1 (en) | 2000-02-24 | 2003-08-19 | Electrocore Techniques, Llc | Method of treating psychiatric diseases by neuromodulation within the dorsomedial thalamus |
US6708064B2 (en) | 2000-02-24 | 2004-03-16 | Ali R. Rezai | Modulation of the brain to affect psychiatric disorders |
US6418344B1 (en) | 2000-02-24 | 2002-07-09 | Electrocore Techniques, Llc | Method of treating psychiatric disorders by electrical stimulation within the orbitofrontal cerebral cortex |
US6473639B1 (en) | 2000-03-02 | 2002-10-29 | Neuropace, Inc. | Neurological event detection procedure using processed display channel based algorithms and devices incorporating these procedures |
US6484132B1 (en) | 2000-03-07 | 2002-11-19 | Lockheed Martin Energy Research Corporation | Condition assessment of nonlinear processes |
US6612983B1 (en) | 2000-03-28 | 2003-09-02 | Medtronic, Inc. | Pancreatic secretion response to stimulation test protocol |
US6768969B1 (en) | 2000-04-03 | 2004-07-27 | Flint Hills Scientific, L.L.C. | Method, computer program, and system for automated real-time signal analysis for detection, quantification, and prediction of signal changes |
US6466822B1 (en) | 2000-04-05 | 2002-10-15 | Neuropace, Inc. | Multimodal neurostimulator and process of using it |
US6826428B1 (en) | 2000-04-11 | 2004-11-30 | The Board Of Regents Of The University Of Texas System | Gastrointestinal electrical stimulation |
DE10018360C2 (en) | 2000-04-13 | 2002-10-10 | Cochlear Ltd | At least partially implantable system for the rehabilitation of a hearing impairment |
US6522928B2 (en) | 2000-04-27 | 2003-02-18 | Advanced Bionics Corporation | Physiologically based adjustment of stimulation parameters to an implantable electronic stimulator to reduce data transmission rate |
US6610713B2 (en) | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US7485095B2 (en) | 2000-05-30 | 2009-02-03 | Vladimir Shusterman | Measurement and analysis of trends in physiological and/or health data |
EP1172125B1 (en) | 2000-07-11 | 2005-03-09 | SORIN BIOMEDICA CRM S.r.l. | An implantable heart stimulation system with automatic mode switching controlled by sympatho-vagal balance |
US7236831B2 (en) | 2000-07-13 | 2007-06-26 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7672730B2 (en) | 2001-03-08 | 2010-03-02 | Advanced Neuromodulation Systems, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7010351B2 (en) | 2000-07-13 | 2006-03-07 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a lasting change in a neural-function of a patient |
US7305268B2 (en) | 2000-07-13 | 2007-12-04 | Northstar Neurscience, Inc. | Systems and methods for automatically optimizing stimulus parameters and electrode configurations for neuro-stimulators |
US7024247B2 (en) | 2001-10-15 | 2006-04-04 | Northstar Neuroscience, Inc. | Systems and methods for reducing the likelihood of inducing collateral neural activity during neural stimulation threshold test procedures |
US7146217B2 (en) | 2000-07-13 | 2006-12-05 | Northstar Neuroscience, Inc. | Methods and apparatus for effectuating a change in a neural-function of a patient |
US6662053B2 (en) | 2000-08-17 | 2003-12-09 | William N. Borkan | Multichannel stimulator electronics and methods |
US6591138B1 (en) | 2000-08-31 | 2003-07-08 | Neuropace, Inc. | Low frequency neurostimulator for the treatment of neurological disorders |
US6487446B1 (en) | 2000-09-26 | 2002-11-26 | Medtronic, Inc. | Method and system for spinal cord stimulation prior to and during a medical procedure |
US7499742B2 (en) | 2001-09-26 | 2009-03-03 | Cvrx, Inc. | Electrode structures and methods for their use in cardiovascular reflex control |
US6615084B1 (en) | 2000-11-15 | 2003-09-02 | Transneuronix, Inc. | Process for electrostimulation treatment of morbid obesity |
US6832114B1 (en) | 2000-11-21 | 2004-12-14 | Advanced Bionics Corporation | Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes |
US6594524B2 (en) | 2000-12-12 | 2003-07-15 | The Trustees Of The University Of Pennsylvania | Adaptive method and apparatus for forecasting and controlling neurological disturbances under a multi-level control |
US6609025B2 (en) | 2001-01-02 | 2003-08-19 | Cyberonics, Inc. | Treatment of obesity by bilateral sub-diaphragmatic nerve stimulation |
US6754536B2 (en) | 2001-01-31 | 2004-06-22 | Medtronic, Inc | Implantable medical device affixed internally within the gastrointestinal tract |
US6775573B2 (en) | 2001-03-01 | 2004-08-10 | Science Medicus Inc. | Electrical method to control autonomic nerve stimulation of gastrointestinal tract |
US7299096B2 (en) | 2001-03-08 | 2007-11-20 | Northstar Neuroscience, Inc. | System and method for treating Parkinson's Disease and other movement disorders |
US6477417B1 (en) | 2001-04-12 | 2002-11-05 | Pacesetter, Inc. | System and method for automatically selecting electrode polarity during sensing and stimulation |
US6684105B2 (en) | 2001-08-31 | 2004-01-27 | Biocontrol Medical, Ltd. | Treatment of disorders by unidirectional nerve stimulation |
US6907295B2 (en) | 2001-08-31 | 2005-06-14 | Biocontrol Medical Ltd. | Electrode assembly for nerve control |
US6671555B2 (en) | 2001-04-27 | 2003-12-30 | Medtronic, Inc. | Closed loop neuromodulation for suppression of epileptic activity |
DE60214698T2 (en) | 2001-04-30 | 2007-09-13 | Medtronic, Inc., Minneapolis | IMPLANTABLE MEDICAL DEVICE AND PLASTER SYSTEM |
US6671547B2 (en) | 2001-06-13 | 2003-12-30 | Koninklijke Philips Electronics N.V. | Adaptive analysis method for an electrotherapy device and apparatus |
US6622038B2 (en) | 2001-07-28 | 2003-09-16 | Cyberonics, Inc. | Treatment of movement disorders by near-diaphragmatic nerve stimulation |
US6622047B2 (en) | 2001-07-28 | 2003-09-16 | Cyberonics, Inc. | Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation |
US6622041B2 (en) | 2001-08-21 | 2003-09-16 | Cyberonics, Inc. | Treatment of congestive heart failure and autonomic cardiovascular drive disorders |
US6760626B1 (en) | 2001-08-29 | 2004-07-06 | Birinder R. Boveja | Apparatus and method for treatment of neurological and neuropsychiatric disorders using programmerless implantable pulse generator system |
US6449512B1 (en) | 2001-08-29 | 2002-09-10 | Birinder R. Boveja | Apparatus and method for treatment of urological disorders using programmerless implantable pulse generator system |
US7054686B2 (en) | 2001-08-30 | 2006-05-30 | Biophan Technologies, Inc. | Pulsewidth electrical stimulation |
US6731979B2 (en) | 2001-08-30 | 2004-05-04 | Biophan Technologies Inc. | Pulse width cardiac pacing apparatus |
US20050137480A1 (en) | 2001-10-01 | 2005-06-23 | Eckhard Alt | Remote control of implantable device through medical implant communication service band |
US7904161B2 (en) | 2001-10-22 | 2011-03-08 | Oscor Inc. | Lead adaptor having low resistance conductors and/or encapsulated housing |
US7050856B2 (en) | 2002-01-11 | 2006-05-23 | Medtronic, Inc. | Variation of neural-stimulation parameters |
US6721603B2 (en) | 2002-01-25 | 2004-04-13 | Cyberonics, Inc. | Nerve stimulation as a treatment for pain |
WO2003072186A2 (en) | 2002-02-01 | 2003-09-04 | The Cleveland Clinic Foundation | Neurostimulation for affecting sleep disorders |
AU2003214965A1 (en) | 2002-02-01 | 2003-09-02 | The Cleveland Clinic Foundation | Method and apparatus for subcutaneously advancing a device between locations |
WO2003066124A2 (en) | 2002-02-01 | 2003-08-14 | The Cleveland Clinic Foundation | Apparatus for facilitating delivery of at least one device to a target site in a body |
US7043305B2 (en) | 2002-03-06 | 2006-05-09 | Cardiac Pacemakers, Inc. | Method and apparatus for establishing context among events and optimizing implanted medical device performance |
AUPS101502A0 (en) | 2002-03-11 | 2002-04-11 | Neopraxis Pty Ltd | Wireless fes system |
US7221981B2 (en) | 2002-03-28 | 2007-05-22 | Northstar Neuroscience, Inc. | Electrode geometries for efficient neural stimulation |
AU2003221553A1 (en) | 2002-04-05 | 2003-10-20 | Oliver Holzner | Method and device for the electromagnetic modification of cerebral activity |
EP1356762A1 (en) | 2002-04-22 | 2003-10-29 | UbiCom Gesellschaft für Telekommunikation mbH | Device for remote monitoring of body functions |
US20050177200A1 (en) | 2002-05-03 | 2005-08-11 | George Mark S. | Method, apparatus and system for determining effects and optimizing parameters of vagus nerve stimulation |
US20060009815A1 (en) | 2002-05-09 | 2006-01-12 | Boveja Birinder R | Method and system to provide therapy or alleviate symptoms of involuntary movement disorders by providing complex and/or rectangular electrical pulses to vagus nerve(s) |
US20060079936A1 (en) | 2003-05-11 | 2006-04-13 | Boveja Birinder R | Method and system for altering regional cerebral blood flow (rCBF) by providing complex and/or rectangular electrical pulses to vagus nerve(s), to provide therapy for depression and other medical disorders |
US20050165458A1 (en) | 2002-05-09 | 2005-07-28 | Boveja Birinder R. | Method and system to provide therapy for depression using electroconvulsive therapy(ECT) and pulsed electrical stimulation to vagus nerve(s) |
US7277761B2 (en) | 2002-06-12 | 2007-10-02 | Pacesetter, Inc. | Vagal stimulation for improving cardiac function in heart failure or CHF patients |
US6934580B1 (en) | 2002-07-20 | 2005-08-23 | Flint Hills Scientific, L.L.C. | Stimulation methodologies and apparatus for control of brain states |
US7006859B1 (en) | 2002-07-20 | 2006-02-28 | Flint Hills Scientific, L.L.C. | Unitized electrode with three-dimensional multi-site, multi-modal capabilities for detection and control of brain state changes |
US7020508B2 (en) | 2002-08-22 | 2006-03-28 | Bodymedia, Inc. | Apparatus for detecting human physiological and contextual information |
US7615010B1 (en) | 2002-10-03 | 2009-11-10 | Integrated Sensing Systems, Inc. | System for monitoring the physiologic parameters of patients with congestive heart failure |
US8512252B2 (en) | 2002-10-07 | 2013-08-20 | Integrated Sensing Systems Inc. | Delivery method and system for monitoring cardiovascular pressures |
WO2004032720A2 (en) | 2002-10-11 | 2004-04-22 | Flint Hills Scientific, L.L.C. | Multi-modal system for detection and control of changes in brain state |
US7204833B1 (en) | 2002-10-11 | 2007-04-17 | Flint Hills Scientific Llc | Multi-modal system for detection and control of changes in brain state |
WO2004034885A2 (en) | 2002-10-15 | 2004-04-29 | Medtronic Inc. | Signal quality monitoring and control for a medical device system |
AU2003301481A1 (en) | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Channel-selective blanking for a medical device system |
AU2003287162A1 (en) | 2002-10-15 | 2004-05-04 | Medtronic Inc. | Configuring and testing treatment therapy parameters for a medical device system |
EP1565102A4 (en) | 2002-10-15 | 2008-05-28 | Medtronic Inc | Synchronization and calibration of clocks for a medical device and calibrated clock |
US8738136B2 (en) | 2002-10-15 | 2014-05-27 | Medtronic, Inc. | Clustering of recorded patient neurological activity to determine length of a neurological event |
US7236830B2 (en) | 2002-12-10 | 2007-06-26 | Northstar Neuroscience, Inc. | Systems and methods for enhancing or optimizing neural stimulation therapy for treating symptoms of Parkinson's disease and/or other movement disorders |
US7302298B2 (en) | 2002-11-27 | 2007-11-27 | Northstar Neuroscience, Inc | Methods and systems employing intracranial electrodes for neurostimulation and/or electroencephalography |
US6959215B2 (en) | 2002-12-09 | 2005-10-25 | Northstar Neuroscience, Inc. | Methods for treating essential tremor |
US7565199B2 (en) | 2002-12-09 | 2009-07-21 | Advanced Neuromodulation Systems, Inc. | Methods for treating and/or collecting information regarding neurological disorders, including language disorders |
EP1603634B1 (en) | 2003-02-03 | 2011-12-21 | Enteromedics Inc. | Electrode band |
US7444183B2 (en) | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
US7162307B2 (en) | 2003-02-11 | 2007-01-09 | Medtronic, Inc. | Channel occupancy in multi-channel medical device communication |
EP1601413B1 (en) | 2003-02-21 | 2006-09-20 | Medtronic, Inc. | Implantable neurostimulator programming with battery longevity indication |
IL154801A0 (en) | 2003-03-06 | 2003-10-31 | Karotix Internat Ltd | Multi-channel and multi-dimensional system and method |
US20060074450A1 (en) | 2003-05-11 | 2006-04-06 | Boveja Birinder R | System for providing electrical pulses to nerve and/or muscle using an implanted stimulator |
US20050187590A1 (en) | 2003-05-11 | 2005-08-25 | Boveja Birinder R. | Method and system for providing therapy for autism by providing electrical pulses to the vagus nerve(s) |
US7444184B2 (en) | 2003-05-11 | 2008-10-28 | Neuro And Cardial Technologies, Llc | Method and system for providing therapy for bulimia/eating disorders by providing electrical pulses to vagus nerve(s) |
US8214043B2 (en) | 2006-08-29 | 2012-07-03 | Matos Jeffrey A | Control of a defibrillator and/or pacemaker |
US7769465B2 (en) | 2003-06-11 | 2010-08-03 | Matos Jeffrey A | System for cardiac resuscitation |
WO2004112894A1 (en) | 2003-06-19 | 2004-12-29 | Advanced Neuromodulation Systems, Inc. | Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
WO2005007120A2 (en) | 2003-07-18 | 2005-01-27 | The Johns Hopkins University | System and method for treating nausea and vomiting by vagus nerve stimulation |
JP4960700B2 (en) | 2003-07-21 | 2012-06-27 | メタキュアー リミティド | Gastrointestinal treatment method and apparatus for use in treating disease and controlling blood glucose |
AU2004261290A1 (en) | 2003-08-01 | 2005-02-10 | Northstar Neuroscience, Inc. | Apparatus and methods for applying neural stimulation to a patient |
US7252090B2 (en) | 2003-09-15 | 2007-08-07 | Medtronic, Inc. | Selection of neurostimulator parameter configurations using neural network |
US7248923B2 (en) | 2003-11-06 | 2007-07-24 | Cardiac Pacemakers, Inc. | Dual-use sensor for rate responsive pacing and heart sound monitoring |
WO2005053788A1 (en) | 2003-12-01 | 2005-06-16 | Medtronic, Inc. | Method and system for vagal nerve stimulation with multi-site cardiac pacing |
US7783349B2 (en) | 2006-04-10 | 2010-08-24 | Cardiac Pacemakers, Inc. | System and method for closed-loop neural stimulation |
US7115096B2 (en) | 2003-12-24 | 2006-10-03 | Cardiac Pacemakers, Inc. | Third heart sound activity index for heart failure monitoring |
US7107097B2 (en) | 2004-01-14 | 2006-09-12 | Northstar Neuroscience, Inc. | Articulated neural electrode assembly |
US7979137B2 (en) | 2004-02-11 | 2011-07-12 | Ethicon, Inc. | System and method for nerve stimulation |
US20050187593A1 (en) | 2004-02-23 | 2005-08-25 | Medtronic, Inc. | Implantable medical device system with communication link to home appliances |
DE102004014694A1 (en) | 2004-03-25 | 2005-10-27 | Universität Bremen | System and device in a tissue of living organisms implantable device for detecting and influencing electrical bio-activity |
US20050222631A1 (en) | 2004-04-06 | 2005-10-06 | Nirav Dalal | Hierarchical data storage and analysis system for implantable medical devices |
US20050228693A1 (en) | 2004-04-09 | 2005-10-13 | Webb James D | Data exchange web services for medical device systems |
US20050245990A1 (en) | 2004-04-28 | 2005-11-03 | Joseph Roberson | Hearing implant with MEMS inertial sensor and method of use |
EP1740267A4 (en) | 2004-04-28 | 2008-06-25 | Transoma Medical Inc | Implantable medical devices and related methods |
US7725196B2 (en) | 2004-05-04 | 2010-05-25 | The Cleveland Clinic Foundation | Corpus callosum neuromodulation assembly |
WO2005107859A1 (en) | 2004-05-04 | 2005-11-17 | The Cleveland Clinic Foundation | Methods of treating medical conditions by neuromodulation of the cerebellar pathways |
WO2005107856A2 (en) | 2004-05-04 | 2005-11-17 | The Cleveland Clinic Foundation | Methods of treating neurological conditions by neuromodulation of interhemispheric fibers |
EP1595497A1 (en) | 2004-05-05 | 2005-11-16 | Drakeley Consulting Llc | Terminal device and wireless data transmission network |
WO2005110215A2 (en) * | 2004-05-10 | 2005-11-24 | Meddorna, Llc | Method and apparatus for processing respiration data and assessing autonomic function |
US7601115B2 (en) | 2004-05-24 | 2009-10-13 | Neuronetics, Inc. | Seizure therapy method and apparatus |
US20050277872A1 (en) | 2004-05-24 | 2005-12-15 | Colby John E Jr | Apparatus and method for mobile medical services |
WO2005117693A1 (en) | 2004-05-27 | 2005-12-15 | Children's Medical Center Corporation | Patient-specific seizure onset detection system |
US20050267550A1 (en) | 2004-05-28 | 2005-12-01 | Medtronic Minimed, Inc. | System and method for medical communication device and communication protocol for same |
US7801611B2 (en) | 2004-06-03 | 2010-09-21 | Cardiac Pacemakers, Inc. | System and method for providing communications between a physically secure programmer and an external device using a cellular network |
US7519430B2 (en) | 2004-06-17 | 2009-04-14 | Cardiac Pacemakers, Inc. | Dynamic telemetry encoding for an implantable medical device |
US7706866B2 (en) | 2004-06-24 | 2010-04-27 | Cardiac Pacemakers, Inc. | Automatic orientation determination for ECG measurements using multiple electrodes |
WO2006019822A2 (en) | 2004-07-14 | 2006-02-23 | Arizona Technology Enterprises | Pacemaker for treating physiological system dysfunction |
US20060020491A1 (en) | 2004-07-20 | 2006-01-26 | Medtronic, Inc. | Batch processing method for patient management |
CA2573785A1 (en) | 2004-07-20 | 2006-02-02 | Medtronic, Inc. | Therapy programming guidance based on stored programming history |
WO2006023688A1 (en) | 2004-08-18 | 2006-03-02 | Medtronic, Inc. | Conversational interface for programmable implant medical device |
DE102004043212A1 (en) | 2004-09-03 | 2006-03-09 | Biotronik Vi Patent Ag | Communication module and method for its operation |
WO2006031899A2 (en) | 2004-09-10 | 2006-03-23 | The Cleveland Clinic Foundation | Intraluminal electrode assembly |
CA2481631A1 (en) | 2004-09-15 | 2006-03-15 | Dspfactory Ltd. | Method and system for physiological signal processing |
US20060064134A1 (en) | 2004-09-17 | 2006-03-23 | Cardiac Pacemakers, Inc. | Systems and methods for deriving relative physiologic measurements |
US8271093B2 (en) | 2004-09-17 | 2012-09-18 | Cardiac Pacemakers, Inc. | Systems and methods for deriving relative physiologic measurements using a backend computing system |
US7340302B1 (en) | 2004-09-27 | 2008-03-04 | Pacesetter, Inc. | Treating sleep apnea in patients using phrenic nerve stimulation |
US7890159B2 (en) | 2004-09-30 | 2011-02-15 | Cardiac Pacemakers, Inc. | Cardiac activation sequence monitoring and tracking |
US7509170B2 (en) | 2005-05-09 | 2009-03-24 | Cardiac Pacemakers, Inc. | Automatic capture verification using electrocardiograms sensed from multiple implanted electrodes |
US7167755B2 (en) | 2004-10-05 | 2007-01-23 | Cardiac Pacemakers, Inc. | Adaptive software configuration for a medical device |
US8175705B2 (en) | 2004-10-12 | 2012-05-08 | Cardiac Pacemakers, Inc. | System and method for sustained baroreflex stimulation |
US8755885B2 (en) | 2004-10-13 | 2014-06-17 | Medtronic, Inc. | Software configurable medical device platform and associated methods |
US7672733B2 (en) | 2004-10-29 | 2010-03-02 | Medtronic, Inc. | Methods and apparatus for sensing cardiac activity via neurological stimulation therapy system or medical electrical lead |
US8244355B2 (en) | 2004-10-29 | 2012-08-14 | Medtronic, Inc. | Method and apparatus to provide diagnostic index and therapy regulated by subject's autonomic nervous system |
ATE481920T1 (en) | 2004-11-02 | 2010-10-15 | Medtronic Inc | METHOD FOR DATA RETENTION IN AN IMPLANTABLE MEDICAL DEVICE |
US20060106430A1 (en) | 2004-11-12 | 2006-05-18 | Brad Fowler | Electrode configurations for reducing invasiveness and/or enhancing neural stimulation efficacy, and associated methods |
US7565200B2 (en) | 2004-11-12 | 2009-07-21 | Advanced Neuromodulation Systems, Inc. | Systems and methods for selecting stimulation sites and applying treatment, including treatment of symptoms of Parkinson's disease, other movement disorders, and/or drug side effects |
WO2006053596A1 (en) | 2004-11-16 | 2006-05-26 | Cardiola Ltd. | Apparatus and method for the cardio-synchronized stimulation of skeletal or smooth muscles |
US20060122864A1 (en) | 2004-12-02 | 2006-06-08 | Gottesman Janell M | Patient management network |
US8374693B2 (en) | 2004-12-03 | 2013-02-12 | Cardiac Pacemakers, Inc. | Systems and methods for timing-based communication between implantable medical devices |
US8209009B2 (en) | 2004-12-17 | 2012-06-26 | Medtronic, Inc. | System and method for segmenting a cardiac signal based on brain stimulation |
US8112153B2 (en) | 2004-12-17 | 2012-02-07 | Medtronic, Inc. | System and method for monitoring or treating nervous system disorders |
US8112148B2 (en) | 2004-12-17 | 2012-02-07 | Medtronic, Inc. | System and method for monitoring cardiac signal activity in patients with nervous system disorders |
US8108038B2 (en) | 2004-12-17 | 2012-01-31 | Medtronic, Inc. | System and method for segmenting a cardiac signal based on brain activity |
US8108046B2 (en) | 2004-12-17 | 2012-01-31 | Medtronic, Inc. | System and method for using cardiac events to trigger therapy for treating nervous system disorders |
US8041418B2 (en) | 2004-12-17 | 2011-10-18 | Medtronic, Inc. | System and method for regulating cardiac triggered therapy to the brain |
US7547284B2 (en) | 2005-01-14 | 2009-06-16 | Atlantis Limited Partnership | Bilateral differential pulse method for measuring brain activity |
DE102005003735B4 (en) | 2005-01-26 | 2008-04-03 | Cerbomed Gmbh | Device for transcutaneous stimulation of a nerve of the human body |
US8600521B2 (en) | 2005-01-27 | 2013-12-03 | Cyberonics, Inc. | Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity |
US20060173493A1 (en) | 2005-01-28 | 2006-08-03 | Cyberonics, Inc. | Multi-phasic signal for stimulation by an implantable device |
WO2006083744A1 (en) | 2005-01-31 | 2006-08-10 | Medtronic, Inc. | Anchoring of a medical device component adjacent a dura of the brain or spinal cord |
CA2599959A1 (en) | 2005-03-01 | 2006-09-08 | Functional Neuroscience Inc. | Method of treating depression, mood disorders and anxiety disorders using neuromodulation |
US7889069B2 (en) | 2005-04-01 | 2011-02-15 | Codman & Shurtleff, Inc. | Wireless patient monitoring system |
US20090048500A1 (en) | 2005-04-20 | 2009-02-19 | Respimetrix, Inc. | Method for using a non-invasive cardiac and respiratory monitoring system |
US20060241725A1 (en) | 2005-04-25 | 2006-10-26 | Imad Libbus | Method and apparatus for simultaneously presenting cardiac and neural signals |
US7640057B2 (en) | 2005-04-25 | 2009-12-29 | Cardiac Pacemakers, Inc. | Methods of providing neural markers for sensed autonomic nervous system activity |
US7561923B2 (en) | 2005-05-09 | 2009-07-14 | Cardiac Pacemakers, Inc. | Method and apparatus for controlling autonomic balance using neural stimulation |
US8391990B2 (en) | 2005-05-18 | 2013-03-05 | Cardiac Pacemakers, Inc. | Modular antitachyarrhythmia therapy system |
CA2609346A1 (en) | 2005-07-28 | 2007-02-15 | The General Hospital Corporation | Electro-optical system, apparatus, and method for ambulatory monitoring |
US20070025608A1 (en) | 2005-07-29 | 2007-02-01 | Cyberonics, Inc. | Enhancing intrinsic neural activity using a medical device to treat a patient |
US20070055320A1 (en) | 2005-09-07 | 2007-03-08 | Northstar Neuroscience, Inc. | Methods for treating temporal lobe epilepsy, associated neurological disorders, and other patient functions |
US20070073346A1 (en) | 2005-09-28 | 2007-03-29 | Giorgio Corbucci | Telemetry of combined endocavitary atrial and ventricular signals |
US8165682B2 (en) | 2005-09-29 | 2012-04-24 | Uchicago Argonne, Llc | Surface acoustic wave probe implant for predicting epileptic seizures |
EP2471451A1 (en) | 2005-10-14 | 2012-07-04 | Nanostim, Inc. | Leadless cardiac pacemaker and system |
US20070088403A1 (en) | 2005-10-19 | 2007-04-19 | Allen Wyler | Methods and systems for establishing parameters for neural stimulation |
US7856264B2 (en) | 2005-10-19 | 2010-12-21 | Advanced Neuromodulation Systems, Inc. | Systems and methods for patient interactive neural stimulation and/or chemical substance delivery |
US8929991B2 (en) | 2005-10-19 | 2015-01-06 | Advanced Neuromodulation Systems, Inc. | Methods for establishing parameters for neural stimulation, including via performance of working memory tasks, and associated kits |
US7729773B2 (en) | 2005-10-19 | 2010-06-01 | Advanced Neuromodualation Systems, Inc. | Neural stimulation and optical monitoring systems and methods |
US20070088404A1 (en) | 2005-10-19 | 2007-04-19 | Allen Wyler | Methods and systems for improving neural functioning, including cognitive functioning and neglect disorders |
US8108048B2 (en) | 2005-11-30 | 2012-01-31 | Medtronic, Inc. | Protocol implementation for telemetry communications involving implantable medical devices |
WO2007066343A2 (en) | 2005-12-08 | 2007-06-14 | Dan Furman | Implantable biosensor assembly and health monitoring system |
US20070135855A1 (en) | 2005-12-13 | 2007-06-14 | Foshee Phillip D | Patient management device for portably interfacing with a plurality of implantable medical devices and method thereof |
WO2007072425A2 (en) | 2005-12-20 | 2007-06-28 | Koninklijke Philips Electronics, N.V. | Device for detecting and warning of a medical condition |
US8046069B2 (en) | 2005-12-22 | 2011-10-25 | Cardiac Pacemakers, Inc. | Method and apparatus for control of cardiac therapy using non-invasive hemodynamic sensor |
US8725243B2 (en) | 2005-12-28 | 2014-05-13 | Cyberonics, Inc. | Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
US8868172B2 (en) | 2005-12-28 | 2014-10-21 | Cyberonics, Inc. | Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders |
US20070149952A1 (en) | 2005-12-28 | 2007-06-28 | Mike Bland | Systems and methods for characterizing a patient's propensity for a neurological event and for communicating with a pharmacological agent dispenser |
US9566447B2 (en) | 2005-12-28 | 2017-02-14 | Cardiac Pacemakers, Inc. | Neural stimulation system for reducing atrial proarrhythmia |
US8827905B2 (en) | 2006-01-04 | 2014-09-09 | General Electric Company | Patient initiated on-demand remote medical service with integrated knowledge base and computer assisted diagnosing characteristics |
US20070156450A1 (en) | 2006-01-04 | 2007-07-05 | Steven Roehm | Networked modular and remotely configurable system and method of remotely monitoring patient healthcare characteristics |
US20080051852A1 (en) | 2006-01-21 | 2008-02-28 | Cerbomed Gmbh | Device and method for the transdermal stimulation of a nerve of the human body |
US7606622B2 (en) | 2006-01-24 | 2009-10-20 | Cardiac Pacemakers, Inc. | Method and device for detecting and treating depression |
US20070287931A1 (en) | 2006-02-14 | 2007-12-13 | Dilorenzo Daniel J | Methods and systems for administering an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
US20070208390A1 (en) | 2006-03-01 | 2007-09-06 | Von Arx Jeffrey A | Implantable wireless sound sensor |
US8209018B2 (en) | 2006-03-10 | 2012-06-26 | Medtronic, Inc. | Probabilistic neurological disorder treatment |
EP2026874B1 (en) | 2006-03-29 | 2015-05-20 | Dignity Health | Vagus nerve stimulation system |
US7496409B2 (en) | 2006-03-29 | 2009-02-24 | Medtronic, Inc. | Implantable medical device system and method with signal quality monitoring and response |
US20070239211A1 (en) | 2006-03-31 | 2007-10-11 | Andras Lorincz | Embedded neural prosthesis |
US8926676B2 (en) | 2006-04-11 | 2015-01-06 | Advanced Neuromodulation Systems, Inc. | Systems and methods for applying signals, including contralesional signals, to neural populations |
US7949401B2 (en) | 2006-04-11 | 2011-05-24 | Advanced Neuromodulation Systems, Inc. | Electromagnetic signal delivery for tissue affected by neuronal dysfunction, degradation, damage, and/or necrosis, and associated systems and methods |
US20070249953A1 (en) | 2006-04-21 | 2007-10-25 | Medtronic, Inc. | Method and apparatus for detection of nervous system disorders |
US7761145B2 (en) | 2006-04-21 | 2010-07-20 | Medtronic, Inc. | Method and apparatus for detection of nervous system disorders |
US8165683B2 (en) | 2006-04-21 | 2012-04-24 | Medtronic, Inc. | Method and apparatus for detection of nervous system disorders |
US20070249956A1 (en) | 2006-04-21 | 2007-10-25 | Medtronic, Inc. | Method and apparatus for detection of nervous system disorders |
US8155742B2 (en) | 2006-04-25 | 2012-04-10 | Medtronic, Inc. | Remote communication system with availability indicator for an implantable medical device |
US7610083B2 (en) | 2006-04-27 | 2009-10-27 | Medtronic, Inc. | Method and system for loop recording with overlapping events |
US7912537B2 (en) | 2006-04-27 | 2011-03-22 | Medtronic, Inc. | Telemetry-synchronized physiological monitoring and therapy delivery systems |
US7764988B2 (en) | 2006-04-27 | 2010-07-27 | Medtronic, Inc. | Flexible memory management scheme for loop recording in an implantable device |
US20070255337A1 (en) | 2006-04-28 | 2007-11-01 | Medtronic, Inc. | Cardiac monitoring via gastrointestinal stimulator |
US7856272B2 (en) | 2006-04-28 | 2010-12-21 | Flint Hills Scientific, L.L.C. | Implantable interface for a medical device system |
NL1031958C2 (en) | 2006-06-07 | 2007-12-10 | Hobo Heeze B V | Personal monitoring system for real-time signaling of epilepsy attacks. |
EP2034885A4 (en) | 2006-06-23 | 2010-12-01 | Neurovista Corp | Minimally invasive monitoring systems and methods |
US20080046038A1 (en) | 2006-06-26 | 2008-02-21 | Hill Gerard J | Local communications network for distributed sensing and therapy in biomedical applications |
US7949404B2 (en) | 2006-06-26 | 2011-05-24 | Medtronic, Inc. | Communications network for distributed sensing and therapy in biomedical applications |
US8170668B2 (en) | 2006-07-14 | 2012-05-01 | Cardiac Pacemakers, Inc. | Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapy |
DE102006033623B4 (en) | 2006-07-18 | 2010-04-08 | Cerbomed Gmbh | System for transcutaneous stimulation of a nerve of the human body |
DE102006036069B4 (en) | 2006-07-18 | 2008-09-04 | Cerbomed Gmbh | Audiological transmission system |
US20080103548A1 (en) | 2006-08-02 | 2008-05-01 | Northstar Neuroscience, Inc. | Methods for treating neurological disorders, including neuropsychiatric and neuropsychological disorders, and associated systems |
US20080046037A1 (en) | 2006-08-18 | 2008-02-21 | Haubrich Gregory J | Wireless Communication Network for an Implantable Medical Device System |
US8111150B2 (en) | 2006-09-08 | 2012-02-07 | Cardiomems, Inc. | Physiological data acquisition and management system for use with an implanted wireless sensor |
US8126529B2 (en) | 2006-09-22 | 2012-02-28 | Advanced Neuromodulation Systems, Inc. | Methods and systems for securing electrode leads |
US20080077028A1 (en) | 2006-09-27 | 2008-03-27 | Biotronic Crm Patent | Personal health monitoring and care system |
US8123668B2 (en) | 2006-09-28 | 2012-02-28 | Bioventrix (A Chf Technologies' Company) | Signal transmitting and lesion excluding heart implants for pacing defibrillating and/or sensing of heart beat |
US20080208291A1 (en) | 2006-10-24 | 2008-08-28 | Northstar Neuroscience, Inc. | Frequency shift keying (fsk) magnetic telemetry for implantable medical devices and associated systems and methods |
US8295934B2 (en) | 2006-11-14 | 2012-10-23 | Neurovista Corporation | Systems and methods of reducing artifact in neurological stimulation systems |
US8096954B2 (en) | 2006-11-29 | 2012-01-17 | Cardiac Pacemakers, Inc. | Adaptive sampling of heart sounds |
US20080139870A1 (en) | 2006-12-12 | 2008-06-12 | Northstar Neuroscience, Inc. | Systems and methods for treating patient hypertonicity |
US8652040B2 (en) | 2006-12-19 | 2014-02-18 | Valencell, Inc. | Telemetric apparatus for health and environmental monitoring |
US20080161712A1 (en) | 2006-12-27 | 2008-07-03 | Kent Leyde | Low Power Device With Contingent Scheduling |
US9913593B2 (en) | 2006-12-27 | 2018-03-13 | Cyberonics, Inc. | Low power device with variable scheduling |
US9898656B2 (en) | 2007-01-25 | 2018-02-20 | Cyberonics, Inc. | Systems and methods for identifying a contra-ictal condition in a subject |
US20080183097A1 (en) | 2007-01-25 | 2008-07-31 | Leyde Kent W | Methods and Systems for Measuring a Subject's Susceptibility to a Seizure |
US20080183245A1 (en) | 2007-01-31 | 2008-07-31 | Van Oort Geeske | Telemetry of external physiological sensor data and implantable medical device data to a central processing system |
WO2008103842A2 (en) | 2007-02-21 | 2008-08-28 | Neurovista Corporation | Methods and systems for characterizing and generating a patient-specific seizure advisory system |
US7747551B2 (en) | 2007-02-21 | 2010-06-29 | Neurovista Corporation | Reduction of classification error rates and monitoring system using an artificial class |
US8068918B2 (en) | 2007-03-09 | 2011-11-29 | Enteromedics Inc. | Remote monitoring and control of implantable devices |
US8036736B2 (en) | 2007-03-21 | 2011-10-11 | Neuro Vista Corporation | Implantable systems and methods for identifying a contra-ictal condition in a subject |
US20080249591A1 (en) | 2007-04-06 | 2008-10-09 | Northstar Neuroscience, Inc. | Controllers for implantable medical devices, and associated methods |
US20080255582A1 (en) | 2007-04-11 | 2008-10-16 | Harris John F | Methods and Template Assembly for Implanting an Electrode Array in a Patient |
US20090054795A1 (en) | 2007-08-22 | 2009-02-26 | Misczynski Dale J | Method for generating three standard surface ecg leads derived from three electrodes contained in the mid-horizontal plane of the torso |
-
2006
- 2006-04-28 US US11/414,391 patent/US7962220B2/en active Active
-
2007
- 2007-04-23 EP EP07755837A patent/EP2019714B1/en not_active Not-in-force
- 2007-04-23 AT AT07755837T patent/ATE512692T1/en not_active IP Right Cessation
- 2007-04-23 WO PCT/US2007/009723 patent/WO2007127150A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4979511A (en) | 1989-11-03 | 1990-12-25 | Cyberonics, Inc. | Strain relief tether for implantable electrode |
US20050049649A1 (en) * | 2002-10-21 | 2005-03-03 | The Cleveland Clinic Foundation | Electrical stimulation of the brain |
WO2004064918A1 (en) * | 2003-01-14 | 2004-08-05 | Department Of Veterans Affairs, Office Of General Counsel | Cervical wagal stimulation induced weight loss |
US20060015153A1 (en) * | 2004-07-15 | 2006-01-19 | Gliner Bradford E | Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2977078A1 (en) | 2014-07-23 | 2016-01-27 | Sorin CRM SAS | Active implantable medical device for therapy by vagus nerve stimulation, with dynamically adjusting stimulation periods |
US10159840B2 (en) | 2014-07-23 | 2018-12-25 | Sorin Crm Sas | Active implantable medical device for nerve stimulation therapy with dynamic adjustment of stimulation periods |
US11389656B2 (en) | 2014-07-23 | 2022-07-19 | Sorin Crm Sas | Active implantable medical device for nerve stimulation therapy with dynamic adjustment of stimulation periods |
Also Published As
Publication number | Publication date |
---|---|
ATE512692T1 (en) | 2011-07-15 |
EP2019714B1 (en) | 2011-06-15 |
US7962220B2 (en) | 2011-06-14 |
EP2019714A1 (en) | 2009-02-04 |
US20070255374A1 (en) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7962220B2 (en) | Compensation reduction in tissue stimulation therapy | |
US11071863B2 (en) | Controlling electrical stimulation therapy | |
EP3389768B1 (en) | High duty cycle electrical stimulation therapy | |
US7454245B2 (en) | Trained and adaptive response in a neurostimulator | |
US7561918B2 (en) | Autocapture in a neurostimulator | |
US8428731B2 (en) | Sequenced therapy protocols for an implantable medical device | |
JP5188494B2 (en) | System and method using multiple timing channels for electrode adjustment during implant stimulator setup | |
US8600521B2 (en) | Implantable medical device having multiple electrode/sensor capability and stimulation based on sensed intrinsic activity | |
US10213604B2 (en) | Controlling electrical stimulation based on evoked compound muscle action potential | |
US20230001208A1 (en) | Determining posture state from ecaps | |
CN114728162A (en) | Subthreshold stimulation based on ECAP detection | |
CN116018085A (en) | Analysis of ECAP signals | |
CN116917002A (en) | Neural stimulation using time staggered cascade of bipolar electrode combinations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07755837 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007755837 Country of ref document: EP |